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1.1 Angiogenesis and cancer 
Angiogenesis, the sprouting of new vessels from the existing vasculature, mainly takes 
place during embryonic development and growth. In the adult it is restricted to distinct 
physiological processes, e.g. wound healing and pregnancy, by a balance of pro- and 
anti-angiogenic factors.1 Unregulated angiogenesis is one of the hallmarks of cancer.2 
Tumor growth is highly dependent on proper supply with oxygen and nutrients and 
removal of metabolic waste. Induction of angiogenesis is therefore paramount for tumor 
survival and proliferation, and tumor size remains limited unless the tumor switches to 
an angiogenic phenotype.3 The tumor activates the “angiogenic switch” by shifting the 
balance from anti-angiogenic to pro-angiogenic signaling in order to sustain its growth.4  
The intent to stop tumor growth and finally starve out the tumor by disruption of tumor 
derived pro-angiogenic signaling has led to anti-angiogenic drugs for anticancer 
therapy. Agents interrupting vascular endothelial growth factor (VEGF) induced 
angiogenesis have already been introduced into tumor therapy and can indeed stop 
tumor growth. The VEGF-neutralizing antibody bevacizumab (Avastin) and the multi-
targeted growth factor tyrosine kinase inhibitors sunitinib (Sutent), sorafenib (Nexavar), 
pazopanib (Votrient) and vandetanib (Caprelsa5, formerly Zactima) have been 
approved for certain metastatic cancer types as monotherapy or in combination with 
chemotherapy.6  
However, in clinical use it has become apparent that anti-angiogenic tumor therapy is 
more challenging than expected: Many tumors are refractory to VEGF-blockade, or 
become resistant during treatment. This evasive resistance7 can be caused by a shift to 
alternative angiogenic signaling pathways due to a pre-existing multiplicity of redundant 
pro-angiogenic signals. Therefore novel targets in angiogenesis need to be identified 
and characterized as a basis for future therapeutic concepts. If and how anti-
angiogenic therapy itself may contribute to increased metastasis is subject to 
investigation.8, 9 
1.1.1 The angiogenic cascade 
The vessel wall of non-growing capillaries consists of a lining of endothelial cells tightly 
interconnected by junction molecules like VE-cadherin and claudin, a basement 
membrane and surrounding pericytes. When the quiescent vessels are activated by 
angiogenic factors which are released from nearby hypoxic (tumor) tissue a series of 
events occurs, as summarized in Figure 1:  
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Figure 1 The angiogenic cascade. Pro-angiogenic factors like vascular endothelial 
growth factor (VEGF) or basic fibroblast growth factor (bFGF) bind to the corresponding 
receptors on endothelial cells and stimulate degradation of extracellular matrix (ECM) by 
secretion of digestive enzymes and initiate proliferation of endothelial cells. Newly formed 
endothelial cell sprouts further proliferate and migrate towards the tumor, navigating along the 
gradient of angiogenic cues. In order to coordinate endothelial cell movement, a tip cell is 
selected equipped with filopodia to sense guidance cues while the subsiding stalk cells 
proliferate and eventually form the lumen.10 Finally, the endothelial cells organize into hollow 
tubes and create a novel basement membrane. At the end, tight junctions and firm contacts to 
the ECM are formed and pericytes and smooth muscle cells are recruited to the mature vessel 
wall.3, 6, 11  
1.2 Function and regulation of Cdks 
Cyclin-dependent kinases (Cdks) are a family of small serine/threonine kinases which 
are only active when they are bound to their regulatory subunits, the cyclins. The 
presence or absence of the activating cyclin is therefore crucial for Cdk kinase activity. 
At least 29 proteins have been designated as cyclins, sharing a conserved “cyclin box”. 
For some classes of cyclins the Cdk binding partner has not yet been identified.12 
The best-characterized members of the Cdk family are involved in cell cycle control: 
the mitotic Cdk Cdk1, and the interphase Cdks Cdk2, Cdk4 and Cdk6. They pair with 
A-, B-, D- and E-type cyclins, whose expression fluctuates during the cell cycle (which 
explains the term “cyclins”) and this way regulates Cdk activity.13 Cdk3 is only little-
studied and is also implicated in cell cycle control. 14 Cdk7, Cdk8, Cdk9, Cdk10, Cdk11, 
Cdk12 and Cdk13 regulate transcription and splicing. They are activated by Cyclin H 
(Cdk7), C (Cdk8), T and K (Cdk9), and cyclins from the L-type (Cdk10-Cdk13). 12, 15-24  
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In a second function, Cdk7 regulates the activity of the cell cycle Cdks: It is part of the 
Cdk-activating kinase (CAK) complex together with Cyclin H and the stabilizing protein 
Mat125 (see Figure 2), and phosphorylates the cell-cycle Cdks in the T-loop for full 
activation.26 Cdk kinase activity can further be modulated by inhibitory phosphorylations 
or endogenous Cdk inhibitors (CKIs), as displayed in Figure 2. 
CKIs regulate the activity of the cell cycle Cdks by direct interaction. The CKIs of the 
INK4 family, p16INK4A, p15INK4B, p18INK4C and p19INK4D, specifically bind the monomeric 
Cdk and thereby prevent activation via cyclins, whereas p21Cip1, p27Kip1 and p57Kip2 
directly inhibit the Cdk-cyclin complex.12 
 
Figure 2 Regulation of cell cycle Cdks. Cdks are only active when bound to their cyclin 
activators. The Cdk-cyclin complexes can be additionally modulated by phosphorylation: 
Phosphorylation by Cdk activating kinase (CAK) in the T-loop of the Cdk enhances kinase 
activity of the complex. By contrast, phosphorylation of a conserved threonine or tyrosine 
residue by Wee1 or Myt1 negatively regulates kinase activity. The Cdc25 phosphatases 
abrogate this inhibitory phosphorylation. Cdk inhibitors from the INK4 or Cip/Kip family block 
kinase activity by either stabilizing the monomeric Cdk or by binding to the cyclin-Cdk complex. 
(P: Phosphorylation, : Kinase activity; adapted from Malumbres & Barbacid12) 
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1.3 Cdk5 as a unique Cdk in charge of cellular 
migration 
1.3.1 Functions of Cdk5 
Cdk5 has been discovered as a neuronal cdc2-like kinase (nclk) in 1992.27 Cdk5 is a 
proline-directed serine/threonine kinase that phosphorylates serine or threonine 
residues directly upstream of a proline, with a preference for a basic residue in the +3 
position and the consensus sequence (S/T)PX(K/H/R).28 Despite its high sequence 
homology with the mitotic Cdk1 (cdc2), Cdk5 is not involved in cell cycle control and 
unique among the Cdks in its regulation and function. Cdk5 deficient mice die 
perinatally due to severe defects in neuronal layering, as Cdk5 is crucial for the 
cytoarchitecture of the CNS.29 On the cellular level, Cdk5 is well-described in neurons 
as the key hub in the dynamic network of trafficking and transport, integrating signals in 
cytoskeletal dynamics during neuronal migration, in synaptic plasticity and synaptic 
vesicle endo- and exocytosis, cell adhesion and axon guidance, neuromuscular 
development and pain signaling.30, 31 Deregulated Cdk5 activity in neurons is a major 
feature of Alzheimer’s disease resulting in the aggregation of neurofibrillary tangles 
comprised of Cdk5-hyperphosphorylated tau.32 Although Cdk5 expression and activity 
is highest in the central nervous system27, Cdk5 is as well expressed in various tissues, 
and an increasing body of research uncovers extraneuronal functions of Cdk5, where it 
is involved in the regulation of migration, cell death and survival, glucose metabolism 
and inflammation. 33, 34  
1.3.2 Regulation of Cdk5 
Monomeric Cdk5 requires the association with a regulatory subunit for activation; the 
known Cdk5 activators p35 and p39 however are no cyclins. It has been shown that 
Cyclin D, E and G bind to but do not activate Cdk5.35-38 The expression and cleavage of 
p35 and p39 essentially determines Cdk5 activity and localization, as displayed in 
Figure 3 for p35.39  
Neuronal growth factor (NGF)40, tumor necrosis factor-alpha (TNF-α)41, 42 and 
interferon-gamma (INF-γ)43 increase transcription and expression of p35 via 
extracellular signal regulated kinase (ERK) / early growth response-1 (Egr-1) mediated 
pathways.  
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Figure 3 Regulation of Cdk5. p35 activates Cdk5 and recruits the p35/Cdk5 complex to 
the membrane, as p35 carries a myristoylation.32, 44 The short-lived p35 is rapidly degraded by 
the ubiquitin-proteasome pathway after phosphorylation by Cdk5.45 The tyrosine kinases c-abl 
(via the adaptor protein cables)46 and fyn47 activate Cdk5 by phosphorylation of tyrosine 15. 
Neurotoxic events activate calpain which cleaves p35 into p2548, 49 and liberates the p25/Cdk5 
complex from the membrane. p25 is more stable than p35 and dislocates Cdk5 activity to the 
cytoplasm, which leads to tau hyperphosphorylation32 (P: Phosphorylation, U: Ubiquitination,  
: Kinase activity; adapted from Dhavan & Tsai39). 
 
p39, which exhibits similar characteristics, is less explored: p39 carries a 
myristoylation44 and is either degraded by the proteasome or cleaved by calpain into 
p2950. p35/Cdk5 and p39/Cdk5 show similar substrate specificity51, although they seem 
to have physiologically distinct functions. The expression patterns of p35 and p39 in the 
developing brain differ52, they locate Cdk5 activity to different subcellular regions44 and 
p39 can compensate only for some but not all functions of p35 in p35 knockout mice.53 
Cdk5 activation by p35 and p39 has mainly been explored in neurons but p35-
dependent Cdk5 activity was detected in several non-neuronal tissues as well.54-58 
Recently, Cyclin I was described as an alternative activator of Cdk5 in podocytes.59 
In addition, Cdk5 regulation is unique in the family of cyclin-dependent kinases in two 
further aspects: 1) The endogenous Cdk inhibitors (CKIs) are not involved in Cdk5 
regulation and modulation. Yet, Cdk5 can phosphorylate and stabilize p27Kip1, which is 
crucial for migration.60, 61 2) Modulation of Cdk5 activity by phosphorylation 
fundamentally differs from the cell cycle Cdks. In contrast to the cell cycle Cdks, 
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phosphorylation by CAK in the T-loop seems dispensable for Cdk5 full activation. CAK 
can phosphorylate Cdk5 on serine 159, but the function of this phosphorylation is 
disputed.62-65 Activity of mitotic Cdks is inhibited by phosphorylation of conserved 
threonine or tyrosine residues (T14 and Y15 in Cdk2) by Wee1 or Myt1 (see Figure 2). 
Cdk5 is phosphorylated on T14 in vitro and this inhibits kinase activity.66 Cdk5 is not 
inhibited by Wee164, but can be phosphorylated at tyrosine 15 by fyn and c-abl.47 46 In 
contrast to the mitotic Cdks, this phosphorylation stimulates Cdk5 activity.  
1.4 Cyclin-dependent kinase inhibitors 
Tumor cells characteristically display limitless replicative potential which is caused by 
alterations in cell-cycle control systems.2 Cdks as prominent regulators of the cell cycle 
exhibit deregulated activity in tumors, resulting from overexpression and mutations in 
cell cycle cyclins and Cdks, as well as from a loss of their endogenous inhibitors, the 
CKIs.67, 68 To target Cdks is therefore a promising strategy in anticancer therapy and 
several approaches are imaginable to alter Cdk activity – either by direct inhibition of 
the catalytic Cdk subunit, or by indirectly modulating regulatory pathways that govern 
Cdk activity, for example binding of cyclins, phosphorylation of the Cdk subunit or 
interaction with the CKIs. Most small molecule Cdk inhibitors interact with the ATP-
binding site of the kinase subunit, which is fundamental for kinase activity. The ATP-
binding site is well conserved among the Cdks which is why adequate Cdk selectivity of 
inhibitors remains a big challenge.69 If selective or broad-spectrum Cdk inhibitors are 
more effective remains under discussion. Established Cdk modulators such as 
flavopiridol (Alvocidib) and roscovitine (CYC202, seliciclib) inhibit a relatively wide 
range of Cdks. Second generation Cdk inhibitors are under preclinical and clinical 
investigation at present. They can be subdivided in three classes: 1) Broad spectrum 
Cdk inhibitors that target both cell cycle and transcriptional Cdks, 2) Selective inhibitors 
of Cdk2 or Cdk4/6 or 3) Compounds with combined activity against Cdks and additional 
kinases with a benefit for anticancer therapy, for example receptor tryrosine kinases or 
Aurora kinases. The most promising strategy for successful therapy with selective or 
combined Cdk inhibitors is very likely depending on the genetic alterations present in 
the tumor. 70  
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1.4.1 Roscovitine 
(R)-roscovitine or CYC-202/seliciclib – in the following referred to as roscovitine – 
belongs to the class of 2,6,9-trisubstituted purines and is one of the best-studied Cdk 
inhibitors.71 
  
Figure 4 Structure of (R)-roscovitine. The arrows indicate how the structure was 
modified for the tested Cdk inhibitors.  
 
It is developed by Cyclacel Pharmaceuticals72 and currently tested in several Phase I 
and Phase II clinical trials for tumor treatment.73 Roscovitine inhibits mainly Cdk1, 
Cdk2, Cdk5, Cdk7 and Cdk9 and exerts anti-mitotic and pro-apoptotic effects in a wide 
range of tumor cells.74 Cell-cycle independent actions of roscovitine mainly derive from 
Cdk5 inhibition and include anti-angiogenic75 and anti-inflammatory76 effects, inhibition 
of cell migration and motility77, 78 and modulation of glucose metabolism.79 
The roscovitine derivatives evaluated for their anti-angiogenic potential were kindly 
provided by V. Krystof and R. Jorda (Palacký University & Institute of Experimental 
Botany, Olomouc, Czech Republic) and the structures are displayed in the Materials 
and Methods section (Figure 5).  
1.5 Aim of the study 
As explained in the previous paragraphs, Cyclin-dependent kinases (Cdks) and their 
activators, the cyclins, control the transitions of the cell cycle, which is deregulated in 
many tumor types.67 Cdk inhibitors like roscovitine or flavopiridol are currently tested in 
clinical trials as anti-proliferative anticancer drugs.  
Anti-angiogenic actions of these Cdk inhibitors have been observed in vitro and in 
vivo.80-82 Recently, it has been demonstrated that the anti-angiogenic effect of the Cdk 
inhibitor roscovitine most likely results from impaired endothelial cell migration. The 
effect on migration was traced down to Cdk5 inhibition which led to Rac1 inactivation 
OH
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N
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N
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and lamellipodia disruption.75 A promising novel strategy in anti-angiogenic therapy 
may therefore be Cdk5 inhibition. Up to date, improved Cdk inhibitors have mainly 
been developed in order to block cancer cell proliferation but have not systematically 
been optimized and evaluated for anti-angiogenic action by Cdk5 inhibition.  
In contrast to the mitotic Cdks, Cdk5 is a cell-cycle independent Cdk that is known to 
control migration of post-mitotic neurons during CNS development.  
With regard to its regulation, Cdk5 is as well unique among the Cdks: First, Cdk5 
activity and subcellular localization is directed by non-cyclin proteins (p35 and p39). 
Second, phosphorylation of a conserved tyrosine 15 decreases activity of mitotic Cdks 
but stimulates Cdk5 activity and third, endogenous Cdk inhibiting proteins (CKIs), 
which control cell cycle Cdks, do not influence Cdk5 activity. Activation of Cdk5 in non-
neuronal cells, as investigated so far, parallels the neuronal Cdk5 activation pathways, 
however distinct mechanisms have been reported as well.54 The mechanisms which 
are responsible for the activation of Cdk5 during endothelial cell migration have not yet 
been explored.  
 
Aims of the study were therefore: 
1. to elucidate the characteristics of Cdk5 regulation during endothelial 
cell migration by investigating the role of the neuronal activators 
p35/p25 and p39/p29 and the tyrosine 15 phosphorylation. 
2. to evaluate the anti-angiogenic potency of novel roscovitine-derived 
Cdk inhibitors in vitro and in vivo, thereby paying particular 
consideration on their potency to inhibit Cdk5. 
 
 
2 MATERIALS AND METHODS 
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2.1 Materials  
2.1.1 Biochemicals, inhibitors, dyes and cell culture reagents 
Table 1  Biochemicals, inhibitors, dyes and cell culture reagents 
Reagent Producer 
Accustain® paraformaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Amphotericin B PAA Laboratories, Pasching, Austria 
BC Assay reagent Interdim, Montulocon, France 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Roti®-Quant Bradford Reagent Carl Roth, Karlsruhe, Germany 
Cdk5/p35, active  Millipore, Billerica, MA, USA,  
Collagen G Biochrom AG, Berlin, Germany 
Collagenase A Biochrom AG, Berlin, Germany 
Complete® mini EDTA free Roche diagnostics, Penzberg, Germany 
Coomassie brilliant blue G250 Carl Roth, Karlsruhe, Germany 
DMEM medium PAA Laboratories, Pasching, Austria 
DMSO AppliChem, Darmstadt, Germany 
Endothelial Cell Growth Medium (ECGM) 
with Supplement Mix  #C-39215 
PromoCell, Heidelberg, Germany 
FCS gold PAA Laboratories, Pasching, Austria 
FluorSaveTM Reagent mounting medium Merck, Darmstadt, Germany 
M199 Medium PAA Laboratories, Pasching, Austria 
NaF  Merck, Darmstadt, Germany 
Na3VO4  ICN Biomedicals, Aurora, OH, USA 
Page RulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin PAA Laboratories, Pasching, Austria 
PMSF  Sigma-Aldrich, Taufkirchen, Germany 
TNF-α human recombinant PeproTech GmbH, Hamburg, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Tween®20 BDH Prolabo, Ismaning, Germany 
VEGF 165 human recombinant PeproTech GmbH, Hamburg, Germany 
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Table 2 Technical equipment 
Name Device Producer 
AB7300 RT-PCR Real-time PCR system Applied Biosystems, Foster 
City, CA, USA 
Axioskop Upright microscope Zeiss, Jena, Germany 
Culture flasks, plates, 
dishes 
Disposable cell culture 
material 
TPP, Trasadigen, 
Switzerland 
Curix 60 Tabletop film processor Agfa, Cologne, Germany 
FACSCalibur Flow cytometer Becton Dickinson, 
Heidelberg, Germany 
LSM 510 Meta Confocal laser scanning 
microscope 
Zeiss, Jena, Germany 
Mikro 22R Table centrifuge Hettich, Tuttlingen, Germany 
Nanodrop® ND-1000 Spectrophotometer Peqlab, Wilmington, DE, 
USA 
Nucleofector II Electroporation device Lonza GmbH, Cologne, 
Germany 
Odyssey 2.1 Infrared Imaging System  LI-COR Biosciences, 
Lincoln, NE, USA 
Olympus BX41 Clinical microscope Olympus, Hamburg, 
Germany 
Polytron PT1200 Ultrax homogenizer Kinematica AG, Lucerne, 
Switzerland 
SpectraFluor PlusTM Microplate multifunction 
reader 
Tecan, Männedorf, Austria 
SunriseTM Microplate absorbance 
reader 
Tecan, Männedorf, Austria 
Vi-CellTM XR Cell viability analyzer Beckman Coulter, Fullerton, 
CA, USA 
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Table 3 Commonly used buffers 
PBS (pH 7.4)  PBS+Mg2+/Ca2+ 
NaCl  132.2 mM  NaCl  137 mM 
Na2HPO4  10.4 mM  KCl 2.68 mM 
KH2PO4  3.2 mM  Na2HPO4  8.10 mM 
H2O   KH2PO4  1.47 mM 
   MgCl2  0.25 mM 
   H2O   
2.1.2 Inhibitors 
The following inhibitors were used for experiments:  
Table 4 Inhibitors 
Compound  Producer 
A-705253.1383 calpain inhibitor Abbott Bioresearch Corp. 
Worcester, MA, USA  
Imatinib (STI571) c-abl inhibitor Selleck Chemicals, Houston, 
TX, USA 
SU665684 src family kinase inhibitor Sigma-Aldrich, Taufkirchen, 
Germany 
(R)-roscovitine Cdk inhibitor Sigma-Aldrich, Taufkirchen, 
Germany 
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2.1.3 LGR compounds 
Novel roscovitine derivatives were synthesized and kindly provided by V. Krystof and 
R. Jorda (Palacký University & Institute of Experimental Botany, Olomouc, Czech 
Republic). 
 
 
Figure 5 Chemical Structures of the tested LGR compounds in comparison to (R)-
roscovitine. The LGR compounds have been modified in comparison to (R)-roscovitine in one 
or more of the following aspects: 1. The purine scaffold has been changed to pyrazolo[4,3-
d]pyrimidine (LGR 1404, 1406, 1407, 1430, 1492, 1667, 1695), with LGR 1404 being a 
bioisoster of (R)-roscovitine. 2. In the aminobenzyl group, an additional ortho amino function is 
present (LGR 1430, 1492, 1695, 1730). 3. The residue at purine C2 or pyrazolo[4,3-d]pyrimidine 
C5 respectively, differs from (R)-roscovitine either in structure and/or stereochemistry. Defined 
configurations are shown in the chemical structures. LGR 1407 contains no stereocenter. 
LGR 1406 and LGR 1430 are an equal mixture of 4 stereoisomers: the trans enantiomers (R,S) 
and (S,R); and the cis enantiomers (R,R) and (S,S).  
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2.2 Cell culture 
2.2.1 Cell culture solutions and reagents 
The following solutions were used for isolation and cultivation of endothelial cells: 
Table 5  Cell culture solutions 
Growth medium  Stopping medium 
ECGM 500 ml  M 199 500 ml 
Supplement Mix  #C-39215 23.5 ml  FCS 50 ml 
FCS gold 50 ml   
 
Penicillin/Streptomycin 5 ml   
 
Amphothericin B 5 ml   
 
 
Freezing medium  Trypsin/EDTA (T/E) 
FCS gold 10 %  Trypsin  0.05 % 
DMSO 10 %  EDTA  0.20 % 
Growth medium   PBS   
 
Collagen G 
  
Collagen G 0.001 %    
PBS     
 
Before use, FCS gold was heat inactivated. First, FCS gold was partially thawed at 
room temperature for 30 min, then completely thawed at 37°C. Heat inactivation was 
carried out at 56°C for 30 min. FCS aliquots were s tored at -20°C  
2.2.2 Endothelial cells 
Endothelial cells (ECs) were cultured under constant humidity at 37°C with 5 % CO 2 in 
an incubator (Heraeus, Hanau, Germany). Cells were routinely tested for mycoplasma 
contamination with the Venor®GeM PCR detection kit (Minerva Biolabs, Berlin, 
Germany). All cell culture flasks, Petri dishes and multiwell plates were coated with 
Collagen G for 30 min in the incubator prior to plating the cells.  
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2.2.2.1 HMEC-1 (Human microvascular endothelial cells) 
The cell line CDC/EU.HMEC-1 was kindly provided by the Centers for Disease Control 
and Prevention (Atlanta, GA, USA). The immortalized HMEC-1 cell line was created by 
transfection of human dermal microvascular endothelial cells with a plasmid coding for 
the transforming SV40 large T-antigen. HMEC-1 were shown to retain endothelial 
morphologic, phenotypic, and functional characteristics.85, 86 HMEC-1 were used for 
endothelial cell proliferation experiments, siRNA transfection and immunoprecipitations 
for kinase assay and LC-ESI-MS/MS. 
2.2.2.2 HUVECs (Human umbilical vein endothelial cells) 
Human umbilical cords were kindly provided by Klinikum München Pasing,  
Frauenklinik München West/Krüsmannklinik, Rotkreuzklinikum München, and 
WolfartKlinik Gräfelfing. After childbirth, umbilical cords were placed in PBS+Ca2+/Mg2+ 
containing penicillin (100 U/ml) and streptomycin (100 µg/ml), and stored at 4°C. Cells 
were freshly isolated every week. The umbilical vein was washed with PBS+Ca2+/Mg2+, 
filled with 0.1 g/l collagenase A, and incubated for 45 min at 37°C. To isolate 
endothelial cells, the vein was flushed with stopping medium and the cell suspension 
was centrifuged (1,000 rpm, 5 min). Afterwards, cells were resuspended in growth 
medium and plated in a 25 cm2 flask (passage #0). After reaching confluency, cells 
were trypsinized and plated in a 75 cm2 flask. Unless otherwise indicated, experiments 
were performed using cells at passage #3. HUVECs were used for all other 
experiments except endothelial cell proliferation experiments, siRNA transfection and 
immunoprecipitations for LC-ESI-MS/MS. 
2.2.3 Passaging 
After reaching confluency, cells were either sub-cultured 1:3 in 75 cm2 culture flasks or 
seeded either in multiwell-plates or dishes for experiments. For passaging, medium 
was removed and cells were washed twice with PBS before incubation with T/E for     
1-2 min at 37°C. Thereafter, cells were gradually d etached and the digestion was 
terminated using stopping medium. After centrifugation (1,000 rpm, 5 min), the pellet 
was resuspended in growth medium and cells were plated. 
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2.2.4 Freezing and thawing 
For freezing, confluent HMEC-1 from a 150 cm2 flask were trypsinized, centrifuged in 
stopping medium (1,000 rpm, 5 min) and resuspended to 2 x 106 cells/ml in ice-cold 
freezing medium. 1.5 ml aliquots were frozen in cryovials. After storage at -80°C for 
24 h, aliquots were moved to liquid nitrogen for long term storage. 
For thawing, a cryovial was warmed to 37°C and the content was immediately 
dissolved in pre-warmed stopping medium. In order to remove DMSO, cells were 
centrifuged (1,000 rpm, 5 min), resuspended in growth medium and transferred to a 
75 cm2 culture flask. 
2.3 Western blot analysis 
2.3.1 Preparation of protein samples 
Endothelial cells were treated as indicated, washed once with ice-cold PBS and 
subsequently lysed in RIPA lysis buffer or in modified RIPA lysis buffer for phospho-
proteins. Immediately, cells were frozen at -80°C. Afterwards, cells were scraped off 
and transferred to Eppendorf tubes (Peske, Aindling-Arnhofen, Germany) before 
centrifugation (14,000 rpm, 10 min, 4°C). Tissue sa mples as positive controls were 
homogenized in lysis buffer with a POLYTRON PT 1200 C homogenizer (Kinematica 
AG, Lucerne, Switzerland), frozen at -80°C and cent rifuged twice (14,000 rpm, 10 min, 
4°C). Protein concentration was determined in the s upernatant using either the BCA or 
the Bradford assay. Afterwards, Laemmli sample buffer (3x) was added and samples 
were heated at 95°C for 5 min. Samples were kept at  -20°C until Western blot analysis. 
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Table 6 Buffers for protein sample preparation 
RIPA buffer   Lysis buffer for phosphoproteins 
Tris/HCl (pH 7.4) 50 mM  Tris/HCl (pH 7.4) 50 mM 
NaCl 150 mM  NaCl 150 mM 
Nonidet NP 40 1%  Nonidet NP 40 1% 
Deoxycholic acid 0.25%  Deoxycholic acid 0.25% 
SDS 0.10%  SDS 0.10% 
H2O   Na3VO4 0.3 mM 
Complete®mini EDTAfree 4.0 mM  NaF 1.0 mM 
PMSF 1.0 mM  β-Glycerophosphate 3.0 mM 
Na3VO4 1.0 mM  Pyrophosphate 10 mM 
NaF 1.0 mM  H2O  
   Complete®mini EDTAfree 4.0 mM 
   PMSF 1.0 mM 
   H2O2 600 µM 
 
5x SDS-sample buffer   3x Laemmli buffer 
Tris/HCl (pH 6.8) 3.125 M  Tris/HCl (pH 6.8) 187.5 mM 
Glycerol 10 ml  SDS 6% 
SDS 5%  Glycerol 30% 
DTT 2%  Bromphenol blue 0.025% 
Pryonin Y 0.025%  H2O  
H2O   β-Mercaptoethanol 12.5% 
2.3.2 Membrane fractionation 
HUVEC lysates were separated into a soluble (cytosolic) and a particulate 
(membranous) fraction, as described previously by Li H et al.87 HUVECs were treated 
as indicated, washed twice with ice-cold PBS+Ca2+/Mg2+, and homogenized in lysis 
buffer. Protein quantification with Bradford Assay was used to obtain equal protein 
amount in the samples. Lysates were centrifuged at 100,000 g and 4°C for 45 min. The 
supernatant (cytosolic fraction) was collected and boiled with 5x SDS sample buffer 
(5 min, 95°C). The pellet was washed in lysis buffe r containing 1.0 M NaCl and 
centrifuged at 100,000 g and 4°C for 20 min. The su pernatant was discarded and the 
pellet was solubilized with lysis buffer containing 20 mM CHAPS at 4°C for 30 min. 
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After centrifugation at 100,000 g and 4°C for 45 mi n, the supernatant was kept as 
membranous fraction and boiled with 5x SDS sample buffer (5 min, 95°C). The 
cytosolic and membranous fractions were used for Western blotting. 
Table 7 Buffer for membrane fractionation 
Membrane fractionation 
lysis buffer 
Tris/HCl (pH 7.5) 50 mM 
EDTA 0.5 mM 
EGTA 0.5 mM 
Glycerol 10 % 
Glutathion 7 mM 
DTT 2 mM 
PMSF 1 mM 
Complete®mini EDTAfree 4 mM 
H2O  
2.3.3 Immunoprecipitation 
Immunoprecipitation for Kinase Assay 
Immunoprecipitations were used in order to obtain active Cdk5 complexes for Cdk5 
kinase assay. Cells or tissue samples were lysed (see 2.3.1) in the indicated lysis 
buffer (Table 6 and Table 8) and kept on ice for 30 min. Thereafter, the samples were 
centrifuged and protein concentrations were determined in the supernatants. Cell 
lysates were incubated with 2 µg of the indicated antibodies over night at 4°C under 
gentle agitation. Thereafter, Protein A (for rabbit IgG) or Protein G (for mouse IgG) 
Agarose beads (Sigma-Aldrich, Taufkirchen, Germany) were washed with lysis buffer 
and 50 µl bead suspension (25 µl packed beads) was added to each sample. After 3 h 
of incubation at 4°C, the beads were spun down and an aliquot of the supernatant was 
collected as binding control and boiled with Laemmli sample buffer (3x) for 5 min at 
95°C. Subsequently, two washing steps with lysis bu ffer and two washing steps with 
kinase buffer were performed, and 50 µl kinase buffer (Table 9) were added to the 
bead pellet. The beads were resuspended in the kinase buffer before taking a 10 µl 
aliquot of the beads as binding control and boiling the aliquot with Laemmli sample 
buffer (3x) for 5 min at 95°C. The rest of the bead s was used for Cdk5 kinase assay.  
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For the HA-immunoprecipitation of the Cdk5-HA transfected cells, the Pierce 
Mammalian HA-Tag IP/Co-IP Kit (Thermo Fisher Scientific, Rockford, IL, USA) was 
used according to the manufacturer’s instructions. The kinase assay reaction was 
carried out directly on the beads.  
Immunoprecipitation for the detection of novel Cdk5-interacting proteins by LC-ESI-
MS/MS 
HMEC-1 were treated as indicated, lysed in the Lysis buffer for phosphoproteins (Table 
6) and immunoprecipitation with Cdk5 mouse monoclonal antibody was performed as 
described in the paragraph above. After three washing steps with lysis buffer, the 
beads were spun down, 25µl Laemmli sample buffer (3x) were added and the samples 
were boiled for 5 min at 95°C and stored at -20°C u ntil gel electrophoresis and 
subsequent analysis.  
Table 8 Lysis buffers for Cdk5 immunoprecipitation/kinase assay 
Kinase assay lysis buffer 1 
(Miyamoto et al.47) 
 Homogenization buffer 
(Menn et al.88) 
HEPES (pH 7.5) 50 mM  MOPS (pH 7.2) 25 mM 
NaCl 150 mM  MgCl2 15 mM 
EDTA 1 mM  EGTA 15 mM 
DTT 1 mM  DTT 2 mM 
MgCl2 20 mM  Na3VO4 1 mM 
Nonidet NP 40 0.5 %  NaF 1 mM 
PMSF 1 mM  β-Glycerophosphate 60 mM 
Na3VO4 1 mM  p-Nitrophenylphosphate 10 mM 
NaF 10 mM  Disodiumphenylphosphate 1 mM 
Leupeptin 1µg/ml  Leupeptin 10 µg/ml 
H2O   Aprotinin 10 µg/ml 
   Soybean trypsin inhibitor 10 µg/ml 
   Benzamidine 100 µM 
   H2O  
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MPER lysis buffer with inhibitors 
mammalian protein extraction reagent 
(MPER), supplied in the HA Co-IP Kit 
PMSF 1 mM 
Na3VO4 1 mM 
NaF 1 mM 
Complete®mini 
EDTAfree 
4 mM 
2.3.4 Cdk5 kinase assay 
Cdk5 for the kinase assay was immunoprecipitated from cell lysates as described in 
2.3.3. Kinase assay mix containing the indicated kinase buffer (Table 9), 2 µM ATP, 
10 µCi 32P-γ-ATP (Hartmann Analytic, Braunschweig, Germany) and 2.5 µg Histone H1 
(Type III from calf thymus, Sigma-Aldrich, Taufkirchen, Germany) as a substrate was 
added to the beads and the enzyme reaction was carried out at 30°C for 20 min. The 
reaction was then terminated by adding 3x Laemmli Sample Buffer and boiling the 
samples for 5 min at 95°C. Aliquots of the samples were loaded onto a 15 % SDS-
PAGE gel and electrophoresis was run at 100 V for 21 min and at 200 V for 60 min. For 
autoradiography, an X-ray film (Super RX, Fuji, Düsseldorf, Germany) was placed on 
the gel for 8 to 48h at -80°C. After exposure, the film was developed with a Curix 60 
Developing system (Agfa-Gevaert AG, Cologne, Germany).  
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Table 9 Kinase buffers used for Cdk5 kinase assay 
Kinase buffer 1  
(modified from Tsai et al.89) 
 Kinase buffer 2 
(Menn et al.88) 
HEPES (pH 7.0) 50 mM  Tris-HCl (pH 7.2) 25 mM 
MgCl2 20 mM  MgCl2 10 mM 
EDTA 0.1 mM  EGTA 1 mM 
DTT 1 mM  DTT 1 mM 
NaF 10 mM  Heparin 50µg/ml 
Na3VO4 1 mM  Na3VO4 1 mM 
PMSF 1 mM  NaF 1 mM 
Leupeptin 1µg/ml  β-Glycerophosphate 60 mM 
H2O   p-Nitrophenylphosphate 10 mM 
   Disodiumphenylphosphate 1 mM 
   Leupeptin 10 µg/ml 
   Aprotinin 10 µg/ml 
   Soybean trypsin inhibitor 10 µg/ml 
   Benzamidine 100 µM 
   H2O  
 
Kinase Buffer 3 (EDTA free) 
(Tsai et al.89) 
HEPES (pH 7.0) 50 mM 
MgCl2 10 mM 
DTT 1 mM 
NaF 1 mM 
Na3VO4 1 mM 
PMSF 1 mM 
β-Glycerophosphate 3 mM 
Complete®mini 
EDTAfree 
4 mM 
H2O  
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2.3.5 Protein Quantification 
In order to employ equal amounts of protein in all samples for Western blot analysis, 
protein concentrations were determined using either the Bicinchoninic Acid (BCA) 
Assay or Bradford Assay. After measurement, protein concentration was adjusted by 
adding Laemmli sample buffer (1x).  
2.3.5.1 Bicinchoninic Acid (BCA) Assay 
Bicinchoninic Acid (BCA) Protein Assay was performed as described previously.90 
10 µl protein samples were incubated with 200 µl BC Assay reagent (BC Assay 
reagents, Interdim, Montulocon, France) for 30 min at 37°C. Absorbance was 
measured at 550 nm (Tecan Sunrise Absorbance reader, TECAN, Crailsheim, 
Germany). Protein standards were obtained by diluting a 2 mg/ml stock solution of 
bovine serum albumin (BSA, Sigma-Aldrich, Taufkirchen, Germany). Linear regression 
was used to determine the actual protein concentration of each sample. 
2.3.5.2 Bradford Assay 
Bradford Assay was performed as described previously.91 10 µl protein samples were 
incubated with 190 µl Bradford solution (Roti®-Quant Bradford Reagent, Carl Roth, 
Karlsruhe, Germany; 1:5 dilution in water) for 5 min. Thereafter, absorbance was 
measured at 592 nm (Tecan Sunrise Absorbance reader, TECAN, Crailsheim, 
Germany). Protein standards were obtained as described above for the BCA Assay. 
2.3.6 SDS-PAGE 
Proteins were separated by discontinuous SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) according to Laemmli et al.92 Equal amounts of protein were loaded on 
discontinuous polyacrylamide gels, consisting of a separation and a stacking gel, and 
separated using the Mini-PROTEAN 3 electrophoresis module (Bio-Rad, Munich, 
Germany). The concentration of RotiphoreseTM Gel 30 (acrylamide) in the separating 
gel was adjusted for an optimal separation of the proteins depending on their molecular 
weights. Electrophoresis was carried out at 100 V for 21 min for protein stacking and at 
200 V for 45 min for protein separation. The molecular weight of proteins was 
determined by comparison with a prestained protein ladder (PageRulerTM, Fermentas, 
St. Leon-Rot, Germany). 
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Table 10 Acrylamide gel concentration and SDS-PAGE buffers  
Separation gel 12%/15%   Stacking gel   
RotiphoreseTM Gel 30 40%/50%  RotiphoreseTM Gel 30 17% 
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM 
SDS 0.1%  SDS 0.1% 
TEMED 0.1%  TEMED 0.2% 
APS 0.05%  APS 0.1% 
H2O   H2O  
 
Electrophoresis buffer 
 
Tris 4.9 mM 
Glycine 38 mM 
SDS 0.1% 
H2O  
2.3.7 Tank electroblotting 
After protein separation, proteins were transferred to a nitrocellulose membrane 
(Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany) by tank electroblotting.93, 
94
 A blotting sandwich was prepared in a box filled with 1x tank buffer as follows: 
cathode – pad – blotting paper – 
separating gel (from SDS-PAGE) – nitrocellulose membrane –  
blotting paper – pad – anode.  
The membrane was equilibrated with 1x tank buffer for 15 minutes prior to running the 
tank blot. Sandwiches were mounted in the Mini Trans-Blot® system (Bio-Rad, Munich, 
Germany), ice-cold 1x tank buffer was filled into the chamber and a cooling pack 
inserted to avoid excessive heat. Transfers were carried out at 4°C, 100 V for 90 min. 
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Table 11 Tank blotting buffer 
5x Tank buffer  1x Tank buffer 
Tris base 240 mM  5x Tank buffer 20 % 
Glycine 195 mM  Methanol 20 % 
H2O   H2O  
2.3.8 Protein detection 
Prior to immunodetection, unspecific protein binding sites were blocked by incubating 
the membrane in 5 % non-fat dry milk powder (Blotto, Carl Roth, Karlsruhe, Germany) 
in PBS for 2 h at room temperature. Subsequently, the membrane was incubated with 
the respective primary antibody at 4°C overnight. A fter four washing steps with PBS 
containing 0.1 % Tween®20 (PBS-T), the membrane was incubated with the secondary 
antibody for 2 h at room temperature, followed by four additional washing steps with 
PBS-T. All steps regarding the incubation of the membrane were performed under 
gentle agitation. In order to visualize the proteins, two different methods have been 
used depending on the labels of the secondary antibodies: enhanced 
chemiluminescence or infrared imaging. 
2.3.8.1 Enhanced chemiluminescence (ECL) 
Membranes were incubated with HRP-conjugated secondary antibodies (Table 14). For 
detection, luminol (5-Amino-2,3-dihydro-1,4-phthalazinedione) was used as a 
substrate. The membrane was incubated with ECL solution for 1 minute protected from 
light. The appearing luminescence was detected by exposure of the membrane to an 
X-ray film (Super RX, Fuji, Düsseldorf, Germany), which was developed with a Curix 60 
Developing system (Agfa-Gevaert AG, Cologne, Germany). 
Table 12 ECL solution 
ECL  
Tris (pH 8.5) 100 mM 
luminol  2.5 mM 
p-Coumaric acid  1 mM 
H2O2 17 µM 
H2O  
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2.3.8.2 Infrared imaging 
Secondary antibodies coupled to IRDyeTM 800 or Alexa Fluor® 680 with emission at 800 
and 700 nm, respectively, were used (Table 14). Incubation and the following washing 
steps were carried out protected from light. Protein bands of interest were detected 
using the Odyssey imaging system (Li-COR Biosciences, Lincoln, NE).  
Table 13 Primary antibodies for Western blot immunodetection 
Antigen Source Dilution In Provider 
β-actin (C4) mouse monocl. 1:1,000 Blotto 5% Millipore 
Cdk5 (DC34) rabbit polycl. 1:1,000 Blotto 1% Invitrogen 
Cdk5 (C-8) rabbit polycl. 1:1,000 Blotto 1% Santa Cruz 
phos.-Cdk5Y15  rabbit monocl. 1:1,000 BSA 5% Epitomics 
p35/p25 (C64B10) rabbit monocl. 1:250 BSA 5% Cell Signaling 
p35/p25 (C-19) rabbit polycl. 1:500 Blotto 1% Santa Cruz 
HA.11 (16B12) mouse monocl. 1:1,000 Blotto 1% Covance 
 
Table 14 Secondary antibodies for Western blot immunodetection 
Antibody Dilution In Provider 
Goat anti-mouse IgG1: HRP 1:1,000 Blotto 1% Biozol 
Goat anti-rabbit HRP 1:1,000 Blotto 1% Dianova 
Goat anti-rabbit HRP 1:1,000 Blotto 1% Biorad 
Alexa Fluor® 680 Goat anti-mouse IgG 1:20,000 Blotto 1% Molecular 
Probes 
Alexa Fluor® 680 Goat anti-rabbit IgG 1:20,000 Blotto 1% Molecular 
Probes 
IRDyeTM 800CW Goat anti-mouse IgG 1:20,000 Blotto 1% LI-COR 
Biosciences 
2.3.9 Quantification of band intensity 
Intensity of Western blot bands detected with enhanced chemiluminescence was 
measured densitometrically with ImageJ Gel analyzer (Version 1.43q; NIH, Bethesda, 
MD, USA).  
Quantification of bands obtained with infrared imaging was carried out with the Quant 
Data function of the Odyssey software. 
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2.4 Protein identification from SDS-PAGE gels 
2.4.1 Coomassie staining 
Table 15 Solutions for Coomassie staining 
Coomassie staining solution  Destaining solution 
Coomassie blue G250 0.3 %  Ethanol 33.3 % 
Ethanol 45 %  Acetic acid 10 % 
Acetic acid 10 %  H2O  
H2O     
 
The SDS-PAGE gel was incubated under gentle agitation in Coomassie staining 
solution for 1 h. The staining solution was removed and the gel was washed in 
destaining solution for several times until the bands became clearly visible. After a last 
washing step in water the gel was kept at 4°C until  protein analysis. 
2.4.2 In-gel tryptic digestion 
The gel band was cut and destained twice with a 1/1 mixture of acetonitrile 
(ACN) / 20 mM ammonium bicarbonate (NH4HCO3) pH 8.5 at 37°C for 30 min. The gel 
slice was dried at room temperature, rehydrated with the addition of 25 mM NH4HCO3 
and then reduced with 10 mM dithiothreitol (DTT) for 30 min at 56°C in darkness. After 
removing the supernatant, 55 mM iodoacetamide (IAA) in 25mM NH4HCO3 was added. 
The reaction of carboxyamidomethylation proceeded for 30 min at RT in darkness. For 
the enzymatic digestion, the gel slice was incubated overnight at 37°C with 200 ng 
trypsin in 20 mM NH4HCO3 pH 8.5. To quench the enzymatic reaction 1 % aqueous 
acetic acid was added. After the digestion, peptides were extracted by incubating the 
slice with 2 % aqueous formic acid (HCOOH) / ACN (1/1) at RT for 20 min and then 
sonicating for 5 min. The extraction procedure was repeated twice. Supernatants were 
pooled and then dried using a Savant Speedvac Plus SC210A apparatus (Thermo 
Scientific, San José CA, USA). 
2.4.3 LC-ESI-MS/MS analysis 
The extracted peptides were dissolved in 0.1 % HCOOH aqueous solution and 
separated with a nano-LC system (Eksigent, Dublin, CA, USA), consisting of 
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autosampler and 2D-nano HPLC devices, coupled to the LTQ-Orbitrap XL mass 
spectrometer (Thermo Scientific, Bremen, Germany) equipped with a nano ESI source. 
The sample was loaded onto a RP-C18 micro column (10 mm x 100 µm i.d.) trapping 
column (Agilent technologies, Santa Clara, CA, USA) and washed for 10 min with 
0.1 % HCOOH at 3 µl/min. The peptides were separated on a nano column 
(75 µm i.d. x 15 cm, capillary column (New Objectives, USA) packed in-house with 
3 µm C18 coated particles). For the liquid chromatography, 0.1 % HCOOH aqueous 
buffer (solvent A) and ACN / 0.1% HCOOH (95/5, v/v) organic buffer (solvent B) were 
used. The peptides were eluted with a linear gradient of solvent B from 2 to 10 % in 
5 min and from 10 to 40 % in 98 min at flow rate of 200 nl/min. The eluted peptides 
were on-line analyzed in ESI-MS and -MSMS positive mode. The mass spectrometer 
was set so that one full scan was acquired in the Orbitrap parallel to the MSMS scans 
in the LTQ linear ion trap. The resolving power of the Orbitrap mass analyzer was set 
at resolution 60000 (FMHW, m/z 400). The fragmentation spectra (MSMS mode) were 
acquired in data dependent mode, five most intensive signal ions (m/z) per scan were 
selected for fragmentation with repeat duration time 30 s and exclusion duration time 
60 s, isolation width (m/z) 2 amu, activation time 30 ms, activation Q 0.250, normalized 
collision energy (V) 35. The chromatographic separation and the spectra acquisition 
were performed in automatic mode, controlled and monitored by Xcalibur software 
(version 2.0.7, Thermo Scientific, San José CA, USA). 
2.4.4 Protein identification 
Prior the submission to protein database (DB) search the MSMS spectra were 
converted in mzData format using a conversion tool embedded in Bioworks software 
(version 3.1, Thermo Scientific, San José CA, USA). The protein database searches 
were performed using the Mascot search engine (www.matrixscience.com). The 
tandem spectra were searched against the protein database SwissProt 15.3 (uniprot 
29.05.09), choosing for taxonomy specimen homo sapiens. The peptide and the 
fragment mass accuracies were set to 20 ppm and 0.6 Da, respectively. Full tryptic 
peptides including one missed cleavage side were accepted. 
Carboxyamidomethylation at cysteine was set as a static modification. Methionine 
oxidation was set as variable modifications. The Mascot database search of the data 
sets was performed with a confidential index over 95 %. 
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2.5 Quantitative real time RT-PCR 
2.5.1 Isolation of mRNA 
Total RNA was extracted from cell and tissue samples using the RNeasy mini Kit 
(Qiagen GmbH, Hilden, Germany) according to the instruction manual. QuiaShredder 
columns (Qiagen GmbH, Hilden, Germany) were used for sample homogenization. 
DNA-digestion was performed during the isolation procedure with the RNase Free 
DNase Set (Qiagen, Hilden, Germany). 
2.5.2 Reverse transcription 
Reverse transcription was performed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, DA, USA) according to the users’ 
manual. Reverse transcription was carried out in a Primus 25 advanced® thermocycler 
(Peqlab Biotechnologie GmbH, Erlangen, Germany), using the cycling protocol 
displayed in Table 16. cDNA was aliquoted and stored at -20°C until used for real time 
RT-PCR. 
Table 16 Reverse transcription 
Temperature Time 
25°C 10 min 
37°C 2 h 
85°C 5 min 
2.5.3 Quantitative real time PCR 
Quantitative real‐time PCR was performed on AB 7300 RealTime PCR system, using 
TaqMan® Gene Expression Mastermix (Applied Biosystems, Foster City, CA, USA). 
The thermal cycling conditions are shown in Table 17. GAPDH primers shown in Table 
18 were designed using the Primer Express® 2.0 software program (Applied 
Biosystems). For p35 and p39, pre-mixed TaqMan® Gene Expression Assays were 
used (See Table 19). PCR on GAPDH was used as reference, and serial dilution of 
cDNA served as standard curves. Fluorescence‐development was analyzed using the 
AB 7300 system software, and calculation of relative mRNA amount was done 
according to Pfaffl et al.95 
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Table 17 Real Time RT-PCR thermal cycling conditions 
Temperature Time Step 
95°C 10 min Amplitaq ® Gold enzyme activation 
95°C 15 sec denature  
PCR (40 cycles) 
60°C 1 min anneal / extend 
 
Table 18 GAPDH Primers and Probe 
GAPDH   
forward human 5’-GGGAAGGTGAAGGTCGGAGT-3’ 
reverse human 5’-TCCACTTTACCAGAGTTAAAAGCAG -3’ 
probe human 6-Fam-ACCAGGCGCCCAATACGACCAA-Tamra 
 
Table 19 TaqMan® Gene Expression Assays 
Target Species Product Id 
p35 human Hs00243655_s1 
p39 human Hs00269563_s1 
2.6 Transfection of cells 
For transient transfection with the indicated siRNA and plasmids, HUVECs or HMEC-1 
were electroporated using the Nucleofector® II device in combination with the HUVEC 
Nucleofector® Kit (both from LONZA Cologne AG, Cologne, Germany). 
2.6.1 Transfection with siRNA 
In order to downregulate p35, HMEC-1 were transiently transfected with p35 siRNA. 
A 4-siRNA duplexes bundle from riboxx (Radebeul, Germany) was used. The 
sequences are shown in Table 20. The duplexes were dissolved in RNAse free water 
to 0.3 µg/l, aliquoted and stored at -80°C. The con centration of siRNA was verified 
using a NanoDrop (Wilmington, DE, USA). Before transfection, equal parts of the four 
duplexes were mixed. 1 x 106 HMEC-1 were suspended in HUVEC Nucleofector® 
Solution and added to 1.2 µg of the siRNA mixture. The mixture of cells and siRNA was 
transferred to a Nucleofector® cuvette and transfection was performed (program A-
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034). Immediately after electroporation, pre-warmed growth medium was added to the 
cuvette. Afterwards, cells were seeded into 24-well plates (250,000 cells per well) for 
scratch assays and into 6-well plates (750,000 cells per well) for real time RT-PCR to 
ensure successful downregulation. 
Table 20 4-siRNA duplexes bundle - sequences 
 5’-3’sequence 3’-5’sequence 
p35-1 AUUAAUGAGUCAAACCAGCCCCC GGGGGCUGGUUUGACUCAUUAAU 
p35-2 AUAAACCACACAUACUCACCCCC GGGGGUGAGUAUGUGUGGUUUAU 
p35-3 ACAUUGGUCUUUGUUCUCCCCC GGGGGAGAACAAAGACCAAUGU 
p35-4 UUACACAAUACUGAUGACCCCC GGGGGUCAUCAGUAUUGUGUAA 
2.6.2 Transfection of plasmids 
To evaluate the effect of a non-phosphorylatable Cdk5 mutant, HUVECs were 
transfected with pEGFP-CDK5Y15F-C1, which was a gift from P. Zelenka (National 
Eye Institute, National Institutes of Health, Bethesda, MD, USA).96 The respective 
control plasmid pEGFP-C1 was purchased from Clontech Laboratories, Mountain View, 
CA, USA. 
For the Cdk5 kinase assay with Pierce Mammalian HA-Tag IP/Co-IP Kit, HUVECs 
were transfected with the following constructs (all purchased from Addgene, 
Cambridge, MA, USA): Cdk5-HA-pCMV-NeoBam,97 (Addgene plasmid 1872) and p35-
myc-pCMV (Addgene plasmid 1347), or the respective backbone vectors. 
For each transfection, 1 x 106 HUVECs were suspended in HUVEC Nucleofector® 
Solution and added to 3 µg plasmid. For co-transfection, a mixture of 1.5 µg Cdk5 
construct and 1.5 µg p35 construct was used. Electroporation was performed in 
analogy to the siRNA experiments. Subsequently, cells were seeded into 24-well plates 
(250,000 cells per well) for scratch assays and FACS, or into 60 mm Petri dishes 
(2 x 106 cells per dish) for immunoprecipitation followed by Cdk5 kinase assay. 
2.7 Flow Cytometry (FACS) 
Transfection efficiency of the GFP-tagged plasmids was evaluated by flow cytometry. 
The measurements were performed on a FACSCalibur (Becton Dickinson, Heidelberg, 
Germany). Cells were illuminated by a blue argon laser (488 nm).  
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Transfected cells were seeded in duplicates into 24-well plates in parallel to the 
migration experiments. After finishing the scratch assay, the cells for FACS transfection 
control were washed with warm PBS, harvested by trypsination and resuspended in 
PBS. Immediately thereafter, 10,000 cells/sample were measured by flow cytometry. 
2.8 Immunocytochemistry and immunohistochemistry 
2.8.1 Immunocytochemistry  
2.8.1.1 Immunocytochemistry and confocal microscopy 
HUVECs were cultured in 8-well µ-slides (ibiTreat, ibidi GmbH, Martinsried, Germany) 
until reaching confluency. Afterwards, the cell layer was scratched and washed twice 
with PBS+Ca2+/Mg2+. The cells were treated as indicated and allowed to migrate for 
8 h. The cells were then washed with PBS and fixed with 4 % parafomaldehyde in PBS 
at room temperature (10 min), followed by permeabilization for 2 min with 0.1 % Triton 
X-100 in PBS. Cells were washed and unspecific binding was blocked with 0.2 % BSA 
in PBS for 15 min. Thereafter, cells were incubated with primary antibody in 0.2 % 
BSA / PBS over night at 4°C. After three washing st eps with PBS, the specimen were 
incubated with the corresponding AlexaFluor®-labeled secondary antibodies or 
rhodamine-phalloidin for f-actin staining in 0.2 % BSA / PBS for 30 min at room 
temperature. Finally, the slides were again washed three times with PBS (5 min), 
embedded in FluorSaveTM Reagent mounting medium and covered with 8 mm x 8 mm 
glass cover slips (custom made by Helmut Saur Laborbedarf, Reutlingen, Germany).  
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Table 21 Primary and secondary antibodies for immunocytochemistry 
Antigen Source Dilution Provider 
cortactin rabbit polyclonal 1:100 Cell Signaling 
Rac1 mouse monoclonal 1:100 Upstate 
 
Antibody Dilution Provider 
Alexa Fluor® 488 Goat anti-rabbit IgG (H+L) 1:400 Molecular Probes 
Alexa Fluor® 633 Goat anti-mouse IgG (H+L), 
highly cross absorbed 
1:400 Molecular Probes 
rhodamine-phalloidin  1:400 Molecular Probes 
 
A Zeiss LSM 510 META confocal microscope (Zeiss, Oberkochen, Germany) was used 
for obtaining immunofluorescence images. 
2.8.1.2 Quantification of lamellipodia 
Confluent layers of HUVECs were scratched and stimulated in 8-well µ-slides as 
described above. The cells were allowed to migrate for 8 h in the presence or absence 
of the respective concentration of the compounds, until clear lamellipodia formation 
was visible in the control. The actin cytoskeleton was then stained with rhodamine-
phalloidin and fluorescence images of the scratches were taken in 10x magnification 
with the Zeiss LSM 510 META. For quantitative evaluation of lamellipodia formation, 
cells with prominent lamellipodia and ruffles were counted with ImageJ (Cell Counter 
plug-in by Kurt De Vos) in relation to the total number of cells at the scratch front. The 
ratio was calculated as number of lamellipodia-positive cells per 100 cells at scratch 
front.  
2.8.2 Immunohistochemistry 
2.8.2.1 Sections of p35 knockout and wild type mice  
Brain, heart, kidney, liver and lung of four p35 knockout mice and three wild type mice 
were used (age between 11 and 15 weeks). All organs, which were perfusion-fixed in 
paraffin, were kindly provided by J. A. Bibb (University of Texas Southwestern Medical 
Center, Dallas, TX, USA). Generation of the p35 k.o. mice is described in Chae et al.98 
The paraffin-fixed organs were sectioned with a rotation microtome (5 µm sections).  
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Table 22 Identification numbers of p35 k.o. and wt mice 
p35 knockout mice wt mice 
008 KO 010 wt 
890 KO 042 wt 
892 KO 891 wt 
893 KO  
2.8.2.2 Hematoxylin-eosin staining 
Sections were treated twice with xylene and each once with ethanol 100 %, 95 % and 
70 % for deparaffinization. Sections were then incubated with Mayer’s Hematoxylin 
Solution (Sigma-Aldrich, Taufkirchen, Germany) for 15 min, watered for 15 min, treated 
with Accustain® Eosin Y Solution Aqueous (Sigma-Aldrich, Taufkirchen, Germany) for 
3 min and finally watered for 3 min. Sections were mounted with FlourSaveTM Reagent 
and covered with 18 mm x 18 mm cover slips (Menzel, Braunschweig, Germany). 
2.8.2.3 Microvessel density of perfusion-fixed and HE stained sections 
To estimate the number of blood vessels in the brain and liver of p35 knockout and wild 
type mice, sections of 4 different p35-deficient mice and sections of 3 different wild type 
mice were used. As the sections were perfusion-fixed, blood vessels could be 
recognized by their particular lumen in the HE-staining. Four images of each brain 
section were taken with the clinical microscope Olympus BX41 (Olympus, Hamburg, 
Germany) with 10x magnification (A = 0.56819712 mm2) and four images of each liver 
section were taken with 40x magnification (A = 0.03551232 mm2).  
Blood vessels were then identified and counted using ImageJ (Cell Counter plug-in). 
Every blood vessel needed to be clearly separated from each other and to show a 
lumen big enough to be identified by human eye. Blood vessels that were truncated 
were also counted. Blood vessels that showed two or more lumina and were identified 
as one connected blood vessel, were counted as only one. The microvessel density 
(MVD) per image was calculated with the formula MVD = n / A with n as the number of 
vessels, and A as the image area, and averaged for each p35 wt or k.o. mouse. 
2.8.2.4 Sections of the HUH7 xenograft tumors 
The mice were sacrificed by neck fracture. Tumors were removed and weighed and 
volume was determined. Afterwards, tumors were fixed with 4 % paraformaldehyde in 
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PBS for one day and with 1 % paraformaldehyde for additional three days prior to 
embedding in paraffin. The paraffin-embedded tumors were sectioned with a rotation 
microtome (5 µm sections). 
2.8.2.5 CD31 immunohistochemistry staining 
The slides were treated three times with xylene, twice with ethanol 100 %, twice with 
ethanol 95 % and twice with distilled water for deparaffinization. For antigen retrieval, 
sections were incubated with Proteinase K Working Solution (Roche, Indianapolis, IN, 
USA, see Table 23) at 37°C for 15 min and at room t emperature for 10 min, and 
washed twice with PBS + 0.05 % Tween®20. Endogenous peroxidase was blocked by 
incubation in 7.5 % hydrogen peroxide for 10 minutes. Subsequently, the slides were 
incubated with Purified Rat Anti-Mouse CD31 antibody (clone MEC 13.3; BD 
Biosciences, Franklin Lake, NJ, USA) diluted 1:100 in PBS. For antibody detection, 
Vectastain® Universal Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) was 
used according to the manual together with ImmPACT™ AEC Peroxidase Substrate Kit 
(Vector Laboratories, CA, USA) as a chromogen. Slides were counterstained with 
hematoxylin for 1 min and washed with distillated water. Finally, the sections were 
mounted with FlourSaveTM Reagent Mounting Medium and covered with 18 mm x 
18 mm cover slips. 
Table 23 Proteinase K solutions 
TE Buffer   Proteinase K stock solution 12 U/ml 
Tris Base (pH 8) 50 mM  Proteinase K 57.2 µl 
EDTA 1 mM  TE Buffer 971.4 µl 
Tween®20 0.05 %  Glycerol 971.4 µl 
H2O     
 
Proteinase K working solution 0.6 U/ml 
Proteinase K stock solution 0.4 ml 
TE Buffer 7.6 ml 
2.8.2.6 Microvessel density of the CD31 stained tumor sections 
Microvessel density per mm2 tumor tissue was determined after CD31 staining of tumor 
sections. For each tumor, four 10x magnification overview images of well vascularized 
areas were taken with the Olympus BX41. For each 10x overview, four detail images at 
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40x magnification (A = 0.03551232 mm2) were taken and CD31 positive stained 
vessels were counted with the ImageJ Cell Counter plug-in. Every blood vessel 
counted needed to be clearly separated from each other and positively stained for 
CD31. Blood vessels that were definitely identified as one connected blood vessel were 
counted as only one. The microvessel density (MVD) per image was calculated with 
the formula MVD = n / A with n as the number of vessels and A as the image area, and 
averaged for each tumor.  
2.9 Angiogenesis assays 
2.9.1 Cell proliferation assay (crystal violet staining assay) 
HMEC-1 were seeded into 96-well-plates (1,500 cells / well). After 24 h, the cells were 
stimulated with the indicated compounds. At the same time point, cells in a reference 
plate were stained with crystal violet, serving as initial cell number. After 72 hours of 
stimulation, cells were fixed and stained with crystal-violet solution for 10 minutes, 
washed with water, and air dried. Crystal violet was eluted with dissolving buffer and 
absorbance was measured at 550 nm (Tecan Sunrise Absorbance reader, TECAN, 
Crailsheim, Germany). 
Table 24 Solutions for proliferation assay 
Crystal violet solution   Dissolving buffer 
crystal violet 0.5 %  sodium citrate 0.1 M 50 % 
methanol 20 %  ethanol 50 % 
H2O     
2.9.2 CellTiter-BlueTM cell viability assay 
HUVECs were seeded in 96-well plates. After reaching confluency, the cells were 
treated for 16 h with the indicated compounds or left untreated as control. After addition 
of CellTiter-BlueTM Reagent (Promega Corporation, Madison, WI, USA), cells were 
incubated for additional 4 h and fluorescence was measured at 560 nm in a plate-
reading photometer (SpectraFluor Plus; Tecan, Crailsheim, Germany). 
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2.9.3 Scratch assay (wound healing assay) 
Cdk inhibitors: 
HUVECs were seeded into a 24-well plate. After reaching confluency, cells were 
scratched using a pipette tip. The wounded monolayers were washed twice with 
PBS+Ca2+/Mg2+ and growth medium containing the indicated concentration of the 
compounds was added.  
siRNA/plasmids 
After transfection, HMEC-1 were seeded into a 24 well plate (250,000 cells per well). 
40 h (siRNA) or 24 h (plasmids) after transfection, cells were scratched, washed twice 
with PBS+Ca2+/Mg2+ and growth medium was readded. 
 
After 16 h (HUVECs) or 8-12 h (HMEC-1) of migration, cells were washed with 
PBS+Ca2+/Mg2+ and fixed with 4 % paraformaldehyde. Images were taken using the 
TILLvisON system (TILL Photonics GmbH, Gräfelfing, Germany) and a CCD-camera 
connected to an Axiovert 200 microscope (Zeiss, Oberkochen, Germany). Quantitative 
image analysis of the cell covered area was done by Wimasis GmbH, Munich.  
2.9.4 Tube formation assay 
Pre-cooled BD MatrigelTM Matrix Growth Factor Reduced (GFR) (BD Biosciences, 
Heidelberg, Germany) was filled into the lower compartment of µ-slide Angiogenesis 
wells (ibidi GmbH, Martinsried, Germany) on ice. For polymerization of the MatrigelTM 
Matrix, the slides were incubated at 37°C for 30 mi n. 12,000 HUVECs/well were 
seeded onto the MatrigelTM and stimulated in quintuplets for 16h. The level of tube 
formation was determined by light microscopy using the TILLvisON system. 
Quantitative image analysis of tube length, number of branching points and tubes was 
done by Wimasis GmbH, Munich.  
2.9.5 Chemotaxis assay 
The effect of the LGR compounds on endothelial cell chemotaxis was determined using 
Collagen IV coated µ-slides Chemotaxis (ibidi, Martinsried, Germany).99 The slides and 
the media were equilibrated overnight in the incubator before the experiment. A 
HUVECs suspension of 5 x 106 cells per ml was seeded into the observation channel of 
the slides according to the protocol, and the cells were allowed to attach for 4 hours. 
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Thereafter, the chambers of the chemotaxis slide were completely filled with serum-
free medium M 199; and growth medium containing 30 % FCS was added to one 
chamber in order to generate an FCS-gradient from 0 % to 10 %. 10 µM of the 
indicated compounds were added both to the M199 and to the 30 % FCS. Chemotaxis 
was observed over 20 hours by live-cell imaging with a Zeiss LSM 510 META confocal 
microscope equipped with a heating stage (EMBLem, Heidelberg, Germany). During 
observation, cells were incubated with constant humidity at 37°C and with 5 % CO 2. 
A time series was collected taking 1 picture every 10 minutes. For cell tracking and 
data analysis, the manual tracking plug-in (Fabrice Cordelieres) and the Chemotaxis 
and Migration Tool (Version 1.01, ibidi, Martinsried, Germany) for ImageJ were used.  
2.9.6 Chorioallantoic membrane (CAM) assay 
Preparation of cellulose discs 
After preparing the cellulose solution, the mixture was autoclaved, resulting in a 
homogenized, clear solution. For each disk, 200 µl of the warm solution were given into 
the preformed circles of the lid of a 96 well plate and allowed to polymerize under a 
laminar air flow for 48 h. Finally, the cellulose disks were removed using tweezers and 
stored in a sterile Petri dish until use. 
Table 25 Cellulose solution 
Cellulose solution 
Hydroxyethyl cellulose (HEC) 2.5 % 
PVP 17 2 % 
PEG 400 2 % 
H2O  
 
Preparation of the eggs and stimulation 
Fertilized white leghorn eggs were incubated for 72 h at 37°C in humidified 
atmosphere. After transferring the growing embryo into a Petri dish, a second 
incubation period of 72 h followed. At day 6, two cellulose discs, one with 
2.5 ng VEGF / 250 nmol compound and the other with 2.5 ng VEGF / DMSO as control 
were placed on one CAM. After 24 h of stimulation, the vascular structure in the 
stimulated areas of the CAM was visualized using a stereomicroscope and a CCD 
camera (Olympus, Munich, Germany) and pictures were taken. 
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2.10 In vivo tumor model 
The HUH7 xenograft tumor model in SCID mice was performed in cooperation with M. 
Günther (Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-
Maximilians-Universität, Munich, Germany).  
2.10.1 Animals and cell line 
Female SCID mice (8-10 weeks) were housed in individually ventilated cages under 
specific pathogen free conditions with a 12 h day/night cycle and with free access to 
food and water. All experiments were performed according to German legislation for 
the protection of animals and approved by the local government authorities. 
The HUH7 cell line was kindly provided by M. Günther (Pharmaceutical Biotechnology, 
Department of Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany) and 
cultured in DMEM medium (PAA, Pasching, Austria) with 10% FCS gold.  
2.10.2 Tumor cell implantation 
HUH7 were harvested with T/E at approximately 70 % confluency. 5 x 106 HUH7 cells 
in 100 µl PBS were injected subcutaneously with a 25 G needle (Braun, Melsungen, 
Germany) into the flank of SCID mice. Animals were checked regularly for tumor 
progression. Tumor volume was determined in situ, using a digital measuring slide 
(Digi-Met, Preisser, Gammertingen, Germany). Length (a), width (b) and height (c) of 
the tumor were measured and tumor volume was calculated by the formula a·b·c·π/6; 
with π/6 as the correction factor for tumor shape.  
2.10.3 Intraperitoneal application of LGR 1407 
The tumors were allowed to become established for 6 days before initiation of 
treatment. On treatment day 1, mice were randomly assigned to the treatment (n=4) or 
the control group (n=3). LGR 1407 was dissolved in DMSO (50 mg/ml) and freshly 
diluted 1:10 with PBS / 40 mM HCl before injection. 30mg/kg/d LGR 1407 solution 
(treatment) or the respective volume of vehicle only (control) was administered 
intraperitoneally with a 25 G needle (Braun, Melsungen, Germany). The mice were 
treated daily from day 1 to day 7.  
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2.10.4 Isolation of tumors 
For investigation of tumor size, mice were sacrificed by neck fracture. Tumors were 
removed and weight and volume was determined. For immunohistochemistry and 
determination of microvessel density according to 2.8.2.6, the tumors were fixed and 
stained according to 2.8.2. 
2.11 Statistical Analysis 
The number of independently performed experiments is stated in the respective figure 
legend. One representative image is shown. Bar graph data are mean values ± SEM. 
Statistical analysis was performed with the GraphPad Prism software version 3.03 
(GraphPad Software, San Diego, CA, USA). Unpaired t test was used to compare two 
groups. To compare three or more groups, one-way ANOVA followed by Dunnett post 
hoc test was used. Values of p < 0.05 were considered statistically significant. 
 
3 RESULTS 
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3.1 Cdk5 regulation in endothelial cell migration 
Our group has previously shown that Cdk5 is a central regulator of endothelial cell 
migration and a potential target for anti-angiogenic compounds.75 Therefore, the first 
part of the study aimed at the elucidation of the regulation of Cdk5 in endothelial cell 
migration. To get a uniform activated migratory cell phenotype for Western blot or Real 
Time RT-PCR, the cells were detached and freshly seeded for spreading, as indicated 
in the graph labels.  
3.1.1 Cdk5 expression level in endothelial cell migration   
First, we tested the basal Cdk5 protein expression in comparison to brain tissue. In 
endothelial cells Cdk5 protein expression was by trend lower than in human cortex 
tissue, but the difference was not statistically significant (Figure 6) 
A         B 
 
Figure 6 Cdk5 protein expression in endothelial cells in comparison to human 
cortex. Cdk5 protein amount was analyzed by Western blot in samples of human cortex (HC), 
confluent HUVECs (HU) and HMEC-1 (HM). β-actin served as a loading control and for 
normalization of protein amount. Relative quantification (A) and one representative image (B) of 
three individual blots are shown. Note the much lower protein loading in the HC sample in 
panel B (n=3, mean ± SEM, p>0.05, One Way ANOVA, Dunnett). 
 
Cdk5 regulation mainly takes place by transcriptional control of its activators p35 and 
p39, only to a minor degree by alteration of Cdk5 expression.39 In order to find out if 
this also accounts for the regulation of Cdk5 in endothelial cell migration, we first 
analyzed whether the protein levels of Cdk5 are changed during endothelial cell 
spreading (Figure 7). The amount of Cdk5 protein was not significantly altered in the 
migration-activated cells in comparison to confluent control. 
1.0
0.8
0.6
0.4
0.2
0
Cd
k5
 
ba
n
d 
in
te
n
si
ty
(x-
fo
ld
 
co
n
tro
l)
1.2
Cdk5
β-actin
HC HU HM
3  RESULTS 45 
A 
 
B 
 
Figure 7 Cdk5 expression in endothelial cells is not changed during spreading. 
HUVECs were freshly seeded and allowed to spread for the indicated time periods or grown to 
confluency as control. Cdk5 protein amount was analyzed by Western blot. β-actin served as a 
loading control and for normalization of protein amount. Relative quantification (A) and one 
representative image (B) of three individual blots are shown (n=3, mean ± SEM, p>0.05, One 
Way ANOVA, Dunnett). 
3.1.2 Cdk5 phosphorylation at tyrosine 15 is not crucial for 
endothelial cell migration 
Cdk5 phosphorylation on tyrosine 15 by the non-receptor tyrosine kinases fyn or c-abl 
enhances Cdk5 activity and stimulates migration in oligodendrocyte precursor cells47 
and neurite outgrowth in cortical neurons46. So we assumed that Cdk5 phosphorylation 
on tyrosine 15 might also be central for endothelial cell migration. First, we determined 
if treatment with the fyn inhibitor SU6656 or with the c-abl inhibitor imatinib affected 
endothelial cell migration. Neither inhibition of fyn nor inhibition of c-abl decreased 
endothelial cell migration (Figure 8). 
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A        B 
 
Figure 8 Neither fyn nor c-abl inhibition affect endothelial cell migration. Confluent 
layers of HUVECs were scratched and allowed to migrate for 16 h in the presence or absence 
of the respective concentration of the inhibitors. The columns indicate the relative area re-
covered by migrating cells. A: Effect of the fyn inhibitor SU6656 B: Effect of the c-abl inhibitor 
imatinib (A and B: n=3, mean ± SEM, p>0.05, One Way ANOVA, Dunnett). 
 
Phosphorylation of Cdk5 on tyrosine 15 might still be crucial for endothelial cell 
migration, because during endothelial cell migration other tyrosine kinases are 
activated which could also phosphorylate Cdk5. Nevertheless, in Western blots we 
found no increase of Cdk5 phosphorylation level during spreading in comparison to 
confluent control (Figure 9). 
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Figure 9 Cdk5 phosphorylation at tyrosine 15 is not increased during spreading. 
HUVECs were freshly seeded and allowed to spread for the indicated time periods or grown to 
confluency as control. Phospho-Cdk5 Y15 and Cdk5 amount were determined by Western blot. 
The ratio pCdk5/Cdk5, normalized to control (A) and one representative image (B) of three 
individual blots are shown. (n=3, mean ± SEM, p>0.05, One Way ANOVA, Dunnett). 
 
Overexpression of a non-phosphorylatable Y15F-Cdk5 in endothelial cells did not lead 
to a decrease in migration as well (Figure 10). Therefore, Cdk5 tyrosine 15 
phosphorylation does not seem to be crucial for endothelial cell migration.  
 
Figure 10 Overexpression of a non-phosphorylatable Cdk5 mutant does not affect 
endothelial cell migration. HUVECs were transfected with the Y15F-Cdk5-EGFP plasmid or 
the empty EGFP vector as a control. 24h after transfection, the cells were scratched and 
allowed to migrate for 16h (n=3, mean ± SEM, p>0.05, t-test). Transfection efficiency of at least 
45% was determined by FACS analysis of GFP positive cells (data not shown). 
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3.1.3 p35 and p39 are not the central Cdk5 activators in 
endothelial cell migration 
3.1.3.1 Neuronal Cdk5 activator p35 is expressed at a low level in endothelial 
cells 
Cdk5, although in the beginning discovered in neurons, has now been described in 
various non-neuronal cell types, for example epithelial cells100, endothelial cells101, 
podocytes54, adipocytes55, pancreatic β-cells79, and several cancer cells56, 57, 102. For 
p35, extraneuronal expression has also been reported.54-58  
As p35 is described as the central regulator of Cdk5, we first determined whether p35 
is present in endothelial cells and compared the amount of p35 mRNA in endothelial 
cells to that in human cortex tissue. The detected amount of p35 mRNA in endothelial 
cells was only about 0.3% of that in brain tissue. p35 protein is present in endothelial 
cells, but to a substantially lesser degree than in brain tissue (Figure 11).  
A        B 
 
Figure 11 In endothelial cells, p35 is expressed at a very low level in comparison to 
brain tissue. A: mRNA from human cortex (HC), confluent HUVECs (HU) and HMEC-1 (HM) 
was isolated and the amount of p35 mRNA was determined by Real Time RT-PCR (n=3, mean 
± SEM, * p<0.05, One Way ANOVA, Dunnett). B: Western blot of p35 protein levels of human 
cortex and confluent HUVECs and HMEC-1. Note the much lower protein loading in the HC 
sample (n=1).  
3.1.3.2 Cdk5 is translocated to the membrane during endothelial cell spreading 
In neurons, Cdk5 is translocated to the membrane when coupled to its activator p35, 
which carries a myristoylation motif that anchors it to the plasma membrane.32, 44 
In endothelial cells, we found an increased amount of Cdk5 in the membrane fraction 
after 45 min cell spreading (Figure 12). 
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Figure 12 Cdk5 is translocated to the membrane during spreading. Confluent 
HUVECs or HUVECs which were allowed to spread for 45 min were lysed for membrane 
fractionation and the amount of Cdk5 in the cytosolic or membranous fraction was determined 
by Western blot. β-actin served as a loading control (confl. = confluent, spr. = 45 min spreading; 
n=3). 
 
On the one hand p35 expression is very low in confluent endothelial cells; and on the 
other hand a translocation of Cdk5 to the membrane takes place during spreading, in a 
similar manner as described in neuronal cells, where this translocation is p35 
dependent. This indicates that p35 expression might be increased during endothelial 
cell migration.  
We found that p35 mRNA levels are elevated in spreading cells in comparison to 
confluent cells, with peaks at 45 and 240 minutes after plating. The Real time RT-PCR 
experiments shown in Figure 13 have been performed under my supervision by Suvi 
Heiskanen for her Master Thesis.  
 
Figure 13 p35 mRNA expression is regulated in spreading cells, with peaks at 45 
and 240 min. HUVECs were freshly seeded for the indicated time periods or as control grown 
to confluency. p35 mRNA amount was analyzed by Real-time RT-PCR (n=3, mean ± SEM, 
* p<0.05, One Way ANOVA, Dunnett).  
3.1.3.3 The pro-angiogenic factor VEGF does not affect p35 protein levels in 
endothelial cells  
To further investigate the potential role of p35 in endothelial cell migration, we tested 
the influence of growth factor signaling on the level of p35. p35 expression has been 
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shown to be under the control of NGF signaling in neurons via an ERK/Egr1 pathway.40 
Treatment with VEGF did not lead to increased levels of p35 (Figure 14). Treatment 
with PDGF-B and bFGF did not augment p35 protein levels as well (data not shown).  
A 
 
B 
 
Figure 14 p35 protein level is not increased upon VEGF treatment. HUVECs were 
serum-starved for 4 h and subsequently treated with 50 ng/ml VEGF for the indicated time 
periods or left untreated as control. p35 protein amount was determined by Western blot. β-actin 
served as a loading control and for normalization of protein amount. Relative quantification and 
one representative image of three individual blots is shown (n=3, mean ± SEM, p>0.05, One 
Way ANOVA, Dunnett). 
3.1.3.4 p35 levels in endothelial cells are regulated by proteasomal degradation 
but not by calpain. 
p35 protein level is known to be controlled by two degradation pathways: On the one 
hand, it can be degraded via the ubiquitin-proteasome pathway after 
autophosphorylation by p35/Cdk5 in a negative feedback loop.45, 103 On the other hand, 
p35 can be cleaved by calpain into p10 and the more stable Cdk5 activator p25, whose 
binding leads to a translocation of Cdk5 from the membrane to the cytosol.48 We 
investigated therefore whether p35 levels in endothelial cells are influenced by 
proteasomal degradation or by calpain activity. Our hypothesis was that the 
degradation of p35 by the proteasome or calpain might be involved in Cdk5 activation 
and redistribution within the cell. Further, inhibiting the degradation of the unstable p35 
protein might be useful for detection. 
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Treatment with the proteasome inhibitor MG132 led to an increase of p35 protein levels 
in HUVECs. Both antibodies used for Western blot are able to detect also the p35 
cleavage product p25 besides p35. The two proteins can be distinguished by their 
molecular weight of 25 kDa or 35 kDa respectively. No 25 kDa band could be detected 
in control cells or after MG132 treatment, which should result in an increased cleavage 
of p35 via the calpain pathway, suggesting that p25 is not present in endothelial cells 
(Figure 15).  
 
Figure 15 p35 protein level increases upon proteasome inhibition. HUVECs were 
treated with 10 µM MG132 for the indicated time periods or left untreated as control. p35 protein 
amount was determined by Western blot. β-actin served as a loading control. p25 is not 
detectable (n=3). 
 
In contrast to the effect of proteasome inhibition, treatment of HUVECs with the calpain 
inhibitor A-705253.13 did not lead to increased p35 protein levels and had no effect on 
endothelial cell migration (Figure 16). 
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A 
 
B 
 
C 
 
Figure 16 p35 protein levels and migration are not affected upon calpain inhibition 
in endothelial cells. A, B: HUVECs were treated with 10 µM of the calpain inhibitor A-
705253.13 for the indicated time periods or left untreated as control. p35 protein amount was 
determined by Western blot. β-actin served as a loading control and for normalization of protein 
amount. Relative quantification (A) and one representative image (B) of three individual blots 
are shown. C: Confluent layers of HUVECs were scratched and allowed to migrate for 16 h in 
the presence or absence of the respective concentration of the calpain inhibitor A-705253.13. 
The columns indicate the relative area re-covered by migrating cells (A-C: n=3, mean ± SEM, 
p>0.05, One Way ANOVA, Dunnett). 
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3.1.3.5 siRNA-mediated downregulation of p35 does not influence endothelial 
cell migration 
Although p35 does not seem to be involved in growth-factor induced signaling in the 
endothelium, the fact that it is regulated in spreading cells implicates a role in 
cytoskeletal rearrangement during endothelial cell migration. To finally elucidate the 
role of p35 in endothelial cell migration, p35 siRNA experiments were performed in 
HMEC-1. A concentration-dependent decrease in migration after Cdk5 inhibition with 
roscovitine was confirmed in the microvascular HMEC-1, comparable to the effect in 
HUVECs (Figure 17). 
 
Figure 17 Cdk5 inhibition leads to decreased migration not only in HUVECs but also 
in HMEC-1. Confluent layers of HMEC-1 were scratched and allowed to migrate for 8-12 h in 
the presence or absence of the respective concentrations of (R)-roscovitine. The columns 
indicate the relative area re-covered by migrating cells (n=3, mean ± SEM, * p<0.05, One Way 
ANOVA, Dunnett).  
 
For the RNAi experiments, p35 downregulation was assured by Real Time RT-PCR. 
p35 downregulation with siRNA did not lead to a decrease of endothelial cell migration 
(Figure 18). 
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    A      B 
 
Figure 18 p35 RNAi knockdown does not affect migration of endothelial cells. 
HMEC-1 were transfected with p35 siRNA or non-targeting (nt) siRNA. 40h after transfection, 
the cells were scratched and allowed to migrate for 8-12h. Downregulation of p35 was assured 
by Real Time RT-PCR. A: The columns indicate the relative area re-covered by migrating cells. 
(n=3, mean ± SEM, p>0.05, t-test). B: Representative images of one scratch assay are shown 
with the corresponding downregulation control. p35 mRNA was reduced by 50-60% in the three 
experiments (single experiment data not shown).  
 
On protein level, the silencing was visible only after treatment with the proteasome 
inhibitor MG132 (Figure 19), due to the short half life of p35. 
 
Figure 19 p35 downregulation can be detected on protein level after proteasome 
inhibition. HMEC-1 were transfected with p35 siRNA or non-targeting (nt) siRNA as a control 
and seeded. After 38 h or 46 h respectively, the cells were treated with 10 µM of the 
proteasome inhibitor MG132 for two hours and then harvested (40 h or 48 h after transfection) 
for Western blot. β-actin served as a loading control (n=1). 
 
As we could detect p39 in endothelial cells at a very low level (Figure 20), we 
hypothesized that p35 downregulation might be compensated by p39 upregulation 
which would mask an effect on migration.53, 98 Yet, no significant increase of p39 mRNA 
levels was found after downregulation of p35 (Figure 21). This demonstrates that p39 
does not compensate p35 downregulation and is probably not crucial for endothelial 
cell migration. 
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Figure 20 In endothelial cells, p39 mRNA is detectable but at an insignificant level in 
comparison to brain tissue. mRNA from human cortex (HC) and confluent HUVECs (HU) was 
isolated and the amount of p39 mRNA was determined by Real Time RT-PCR. Lower panel: 
Agarose gel bands of p39 RT-PCR product (n=1). 
 
Figure 21 Downregulation of p35 does not lead to upregulation of p39. HMEC-1 were 
transfected with p35 siRNA or non-targeting (nt) siRNA as a control and harvested 40 h after 
transfection .The relative expression of p39 mRNA was determined by Real Time RT-PCR. p35 
downregulation of 50-60% was assured in the p35 siRNA samples by Real Time RT-PCR (n=3, 
mean ± SEM, p>0.05, t-test). 
3.1.3.6 p35 knockout mice do not show visible defects in their vascular 
phenotype 
In order to finally clarify the role of p35 in endothelial cell migration and angiogenesis in 
vivo, we investigated the vascular phenotype of p35 deficient mice. p35 knockout mice 
are viable and show defects in the cortical layering similar to Cdk5 deficient mice.98 To 
detect severe defects in vascular patterning in p35 k.o. mice, organ sections of brain, 
heart, lung, liver and kidney were stained for CD31 and analyzed. No obvious 
differences in vessel patterning were found between the wild type and p35 mice. Figure 
22A displays representative images of liver and kidney sections. For quantitative 
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evaluation, the vessel density was determined for brain and liver sections. No 
significant difference in vessel density between wild type and p35 k.o. mice could be 
detected (Figure 22B and C). The experiments for Figure 22 were performed under my 
supervision by Tanja Tran for her Bachelor Thesis. 
A 
 
B        C 
 
Figure 22 p35-deficient mice display a regular vascular phenotype. A: Representative 
images of liver and kidney of wild type and p35 -/- mice (40x magnification; red: CD31 staining; 
blue: nuclei). B: Representative images of the cortex and liver of wild type and p35 -/- mice 
(cortex: 10x magnification; liver: 40x magnification; HE staining). C: Vessel density of cortex and 
liver, determined in the HE-stained sections and expressed as vessels / mm2 (wt: n=3, p35 -/-: 
n=4, mean ± SEM, p>0.05, t-test).  
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3.1.3.7 TNF does not affect p35 levels in endothelial cells  
The previous results excluded p35 as the crucial regulator of Cdk5 in endothelial cell 
migration and angiogenesis. Recently, our group was able to show that Cdk5 inhibition 
targets the endothelium in a second central process: Cdk5 is responsible for the 
regulation of inflammation, where it is in control of TNF-α-induced expression of 
adhesion molecules in endothelial cells.76 Therefore we hypothesized that p35 might 
not be central for Cdk5 regulation in endothelial cell migration but in inflammatory 
activated endothelial cells. For this reason we tested whether TNF-α treatment of 
endothelial cells leads to an increase of p35 expression, as it has been shown for 
PC12 cells and adipocytes.41, 42  
In HUVECs, TNF-α treatment for short and long periods did not cause a significant 
elevation of p35 protein levels (Figure 23). 
58  3  RESULTS  
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Figure 23 p35 protein levels are not significantly increased upon TNF-α treatment. 
HUVECs were treated with 10 ng/ml TNF-α for the indicated time periods or left untreated as 
control. p35 protein amount was determined by Western blot. β-actin served as a loading 
control and for normalization of protein amount. Relative quantification and representative 
image of at least three individual blots is shown (A and B: n≥3, mean ± SEM, p>0.05, One Way 
ANOVA, Dunnett). 
3.1.4 Cdk5 kinase activity in endothelial cells  
Inhibition of Cdk5 kinase activity both by roscovitine and overexpression of a dominant 
negative kinase dead D144N-Cdk5 mutant decreases endothelial cell migration, as well 
as Cdk5 downregulation by siRNA.75 These findings point to a crucial role of Cdk5 
activity during endothelial cell migration. In order to measure Cdk5 activity, we set up a 
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kinase assay according to the following procedural method: Immunoprecipitation of 
Cdk5 (or p35) – kinase reaction with [γ-32P]-ATP and Histone H1 as a substrate – SDS-
PAGE and autoradiography, as previously described in different variations.104 
3.1.4.1 Cdk5 immunoprecipitation 
Cdk5 was precipitated as described in the Materials and Methods section, using a 
Cdk5 mouse monoclonal antibody (Invitrogen, Carlsbad, CA, USA), Kinase assay lysis 
buffer 1 and Kinase buffer 1. To assure Cdk5-specific activity, 10 µM roscovitine were 
added to one probe as negative control. Successful immunoprecipitation was verified 
by Western blot.  
In this setting, only a weak signal was obtained, and the negative control did not 
consistently differ from the samples (Figure 24).  
 
Figure 24 Kinase Assay after Cdk5 immunoprecipitation. HUVECs were freshly 
seeded, allowed to spread for the indicated time periods, and lysed in Kinase assay lysis 
buffer 1. Cdk5 activity was assayed after Cdk5 immunoprecipitation in Kinase buffer 1. 10 µM 
roscovitine were added to one assay reaction as negative control. Western blot for Cdk5 served 
as immunoprecipitation control (n=3). 
3.1.4.2 p35 immunoprecipitation 
In order to obtain a higher amount of active kinase, we changed the protocol to 
immunoprecipitation of the putative activator p35, as we had not yet fully excluded p35 
for Cdk5 activation in endothelial cell migration. 
The lysis conditions were altered to avoid disruption of the Cdk5/p35 complex: 
detergent-free Homogenization buffer and sonication were used for the lysis, and the 
kinase reaction was carried out in Kinase buffer 2 according to the protocol of S. Bach 
(Station Biologique, Roscoff, Bretagne, France, personal communication). The amount 
of roscovitine was increased in order to assure complete inhibition (Figure 25). 
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Figure 25 Kinase Assay after p35 immunoprecipitation. HUVECs were freshly seeded, 
allowed to spread for the indicated time periods, and lysed in Homogenization buffer. Cdk5 
activity was assayed after p35 immunoprecipitation in Kinase buffer 2. p35 immunoprecipitation 
from mouse brain tissue lysate served as positive control. 100 µM roscovitine were added to 
one assay reaction as negative control. (n=4).  
 
The positive control from brain consistently displayed a very strong signal. This 
confirms the functioning of the assay. For the endothelial cell samples, the signal was 
consistently similar to the negative control. Densitometric quantification of the signals 
with the roscovitine control as zero point showed no significant differences and resulted 
partly in negative values (data not shown). 
In order to rule out that the weak signal in endothelial cells was due to unspecific 
binding, we compared immunoprecipitations with p35, Cdk5, irrelevant rabbit polyclonal 
IgG and beads only from endothelial cells. The autoradiography (Figure 26) showed no 
difference in the signal.  
 
Figure 26 Kinase activity after IP. HUVECs were freshly seeded, allowed to spread for 
15 min, and then lysed in Homogenization buffer. Cdk5 activity was assayed after p35 (p35) or 
Cdk5 (Cdk5) immunoprecipitation or mock IP with irrelevant IgG (IgG) or no IgG (-) in Kinase 
buffer 2. (n=1). 
3.1.4.3 Cdk5 overexpression 
According to our previous findings, we concluded that Cdk5 activity in endothelial cells 
is present, but probably very weak. In order to increase the Cdk5 amount and activity, 
we overexpressed Cdk5 in endothelial cells. To reduce unspecific binding, we used a 
HA-tagged Cdk5 together with the Pierce ProFoundTM Mammalian HA-tag IP/Co-IP kit, 
where the anti-HA antibody is directly coupled to the beads without Protein A or G.  
The kinase assay was carried out in Kinase Buffer 3 directly on the beads. A 
comparable approach is used in Brinkkoetter et al.59 Overexpression of Cdk5-HA and 
equal loading was assured by Western blot of the supernatants for Cdk5 and β-actin, 
respectively. In order to check if a “dilution effect” in the activator/Cdk5 ratio caused by 
MB rosc 15’ 30’ 45’ 60’
cell spreading
p35 - Cdk5 IgG
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Cdk5 overexpression would decrease the signal, we also co-transfected Cdk5-HA with 
p35-myc. Cells transfected with the empty vector were used as negative control. 
Overexpression of Cdk5-HA did not lead to a stronger signal in comparison to negative 
control (empty vector). p35-myc co-expression with Cdk5-HA did also not result in an 
increased signal (Figure 27).  
 
 
Figure 27 Kinase activity after Cdk5-HA overexpression and HA 
immunoprecipitation. HUVECs were transfected with Cdk5-HA only, Cdk5-HA and p35-myc or 
empty vector as control. Kinase activity was assayed after immunoprecipitation with the 
ProFoundTM Mammalian HA-tag IP/Co-IP kit in Kinase Buffer 3. Overexpression of plasmids and 
equal loading was confirmed in the supernatant by Western blot for HA-tag, p35 and β-actin. 
(Cdk5-HA overexpression: n≥3, Cdk5-HA/p35-myc co-transfection: n=1) 
3.1.4.4 Evaluation of different Cdk5 antibodies with recombinant Cdk5/p35 
To finally exclude that the IP procedure and the buffers would interfere with Cdk5 
activity, we first tested the used buffers with an active recombinant Cdk5/p35 complex 
(Millipore, Billerica, MA, USA). An additional set of a lysis and a kinase buffer was also 
tested, which had been used for Cdk5 kinase assay in endothelial cells by Cho et al.105 
(data not shown). Kinase assay lysis buffer 1 and Kinase buffer 3 were chosen for the 
evaluation of antibodies.  
We compared the previously used mouse monoclonal Cdk5 antibody with a rabbit 
polyclonal Cdk5 (C-8) and a mouse monoclonal Cdk5 (J-3) antibody (both from Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). IP with beads only served as a negative 
control. As a positive control, 20 ng of active recombinant Cdk5/p35 were added to one 
lysate before the IP. All antibodies were able to immunoprecipitate the recombinant 
Cdk5 activity. However no difference between Cdk5 immunoprecipitation (IP) and 
unspecific IP was detected in the endothelial cell lysates (Figure 28). 
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Figure 28 Evaluation of Cdk5 antibodies for Cdk5 kinase assay. For Cdk5 (Inv.) and 
Cdk5 (J-3) HMEC-1 lysates, and for Cdk5 (C-8), HUVEC lysates obtained with Kinase assay 
lysis buffer 1 were used for immunoprecipitations with or without active recombinant Cdk5/p35 
added as indicated in the figure legend. Immunoprecipitation without IgG served as negative 
control. Kinase activity was assayed in Kinase buffer 3. (n=1). 
3.1.5 A proteomics approach to reveal novel Cdk5 interacting 
proteins 
According to the experimental data up to now, Cdk5 regulation in endothelial cells 
seems to differ from the “canonical” pathway with p35 and p39 as central activators. 
For detection of significant levels of Cdk5 kinase activity, it is important to identify the 
endothelial specific activator(s), as immunoprecipitation of activators leads to increased 
Cdk5 kinase activity in the assay. 
In order to find novel Cdk5 interacting proteins, we used immunoprecipitation of Cdk5 
and a proteomics approach after separation of the samples in SDS-PAGE gels. For this 
experiment, we compared confluent and 45 min spreading HMEC-1 as well as starved 
and FCS treated HMEC-1. Figure 29 shows the Coomassie stained SDS-PAGE gel 
after Cdk5 immunoprecipitation. Cdk5 is clearly precipitated as a band at 33 kDa is 
visible in the precipitation samples in comparison to IgG IP. The bands marked in 
Figure 29B and C appear to be regulated upon spreading or stimulation with FCS.  
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Figure 29 Coomassie stained SDS-PAGE gel after CDK5 immunoprecipitation. A: In 
comparison to negative control IP (IgG/confl., lane 6), precipitated Cdk5 is present as a 33kDa 
band. B: At 40-50 kDa, a weak negatively regulated band can be seen. C: At about 75 kDa a 
pair of bands is visible, positively regulated during spreading or FCS stimulation. 
 
Bands A, B and C were kindly analyzed by G. Maccarrone in the laboratory of C. Turck 
(Max Planck Institute of Psychiatry, Munich). The results are displayed on the next 
page in Table 26.  
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Table 26 Proteins co-immunoprecipitated with Cdk5 and identified by LC-ESI-MS/MS. 
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3.2 Novel Cdk inhibitors with increased Cdk5 
selectivity show anti-angiogenic effects in vitro and 
in vivo 
We identified Cdk5 as a novel target in endothelial cell migration and angiogenesis 
using roscovitine as a molecular tool. Roscovitine does however not only inhibit Cdk5 
but also Cdk2, further Cdk1, Cdk7 and Cdk9.106, 107 Therefore, we tested novel 
roscovitine derivatives in order to identify highly potent anti-angiogenic Cdk inhibitors 
with an increased selectivity for Cdk5. The compounds LGR 1404, LGR 1406, 
LGR 1407, LGR 1492, LGR 1667, LGR 1695 and LGR 1730 were kindly provided by V. 
Krystof and R. Jorda (Palacký University & Institute of Experimental Botany, Olomouc, 
Czech Republic). For the chemical structures see the Materials and Methods section 
(Figure 5).  
3.2.1 The LGR compounds do not show acute toxicity on 
endothelial cells 
To rule out potential toxic effects, the impact of the novel Cdk inhibitors on cell viability 
was tested. No lower cell viability was found for 10 µM of each of the inhibitors in 
comparison to control. By contrast, 30 µM of LGR 1404, 1406, 1407, 1492, 1695 and 
1730 displayed a weak but significant decrease of viability. Therefore, in the functional 
assays, the effects at 10 µM were used as selection criterion (Figure 30).  
 
Figure 30 The tested LGR compounds do not affect cell viability of endothelial cells 
in the concentration range used in the functional assays. Confluent HUVECs were treated 
for 16 h with the indicated compounds or left untreated as control. Cell viability was determined 
in CellTiter-BlueTM assays (n=3, mean ± SEM, * p<0.05, One Way ANOVA, Dunnett). 
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3.2.2 The LGR compounds inhibit endothelial cell proliferation 
 
Figure 31 The LGR compounds concentration-dependently inhibit endothelial cell 
proliferation. HMEC-1 were left untreated as control or treated with 0.3-1-3-10-30 µM of the 
indicated LGR Cdk inhibitors. After 72 h, cell proliferation was determined by crystal violet 
staining (n=3, mean ± SEM, IC50 values calculated with Graph Pad Prism). 
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As a first screening step, the novel inhibitors were tested in crystal violet proliferation 
assays with HMEC-1 (Figure 31). All eight compounds concentration-dependently 
showed an impact on endothelial cell proliferation, with an IC50 between approximately 
1 µM (LGR 1406) and 20 µM (LGR 1730).  
3.2.3 LGR 1404, 1406, 1407 and 1492 significantly reduce 
endothelial cell migration at a concentration of 10 µM 
Endothelial cell migration is the subsequent crucial step in angiogenesis after the 
activation of the quiescent endothelial cells to proliferate. All eight LGR compounds 
were tested for their effect on migration at 10 µM and 30 µM. LGR 1404, 1406, 1407 
and 1492 were able to significantly decrease endothelial cell migration at 10 µM. 
Treatment with 10 µM of the most potent substances, LGR 1406 and 1407, reduced 
migration by 51 % and 31 %, respectively (Figure 32).  
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A 
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Figure 32 The four compounds LGR 1404, 1406, 1407 and 1492 significantly reduce 
endothelial cell migration at 10 µM. Confluent layers of HUVECs were scratched and the cells 
were allowed to migrate for 16 h in the presence or absence of the respective concentration of 
the compounds. A: The columns indicate the area re-covered by migrating cells. (n=3, mean ± 
SEM, * p<0.05, One Way ANOVA, Dunnett). B: Scratches at endpoint, representative images 
taken out of three experiments.  
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3.2.4 LGR 1404, 1406, 1407 and 1492 concentration-
dependently inhibit tube formation 
The most powerful compounds from the migration experiments, LGR 1404, 1406, 1407 
and 1492 were chosen for tube formation assays. 10 µM of LGR 1404, 1406 and 1407 
showed a significant reduction of tube and branching point numbers as well as of total 
tube length. LGR 1406 and 1407 again showed the strongest effects. 10 µM of 
LGR 1406 decreased tube length and number of branching points by 56 %, and the 
tube number by 42 %. Treatment with 10 µM of LGR 1407 resulted in an about 30 % 
reduction of tube number and total tube length; and to a 35 % reduction in the number 
of branching points (Figure 33). 
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C 
 
Figure 33 LGR 1404, 1406, 1407 and 1492 concentration-dependently inhibit tube 
formation. HUVECs were seeded onto a matrix of growth-factor reduced MatrigelTM in the 
presence or absence of the compounds in the respective concentration. After 16h, images were 
taken and tube characteristics were quantified. A: Number of tubes B: Number of branching 
points C: Tube total length (A, B, C: n=3, mean ± SEM, * p<0.05, One Way ANOVA, Dunnett). 
3.2.5 Overall motility of HUVECs in a chemotactic gradient is 
affected by LGR 1404, 1406 and 1407 
LGR 1404, 1406 and 1407 inhibit endothelial cell migration and also tube formation, 
where cytoskeletal rearrangement and migration-like processes take place as well.  
In order to study the impact of LGR 1404, 1406 and 1407 on migration in more detail, 
chemotaxis experiments in an FCS gradient were performed with HUVECs in the 
presence of 10 µM of the respective compound. Cell paths were analyzed for 
accumulative and Euclidean distance, velocity and y-forward migration index. 
Accumulative distance maps the complete distance a cell migrates, whereas the 
Euclidean distance represents the linear distance between starting and end point of 
migration. The y-forward migration index describes the orientation in the chemotactic 
gradient. All three compounds led to a decrease in accumulative distance and velocity, 
which are indicators for general cell motility. Orientation did not seem to be clearly 
affected, as the y-forward migration index was not significantly reduced. However, the 
Euclidean distance, as a second indicator for orientation, was decreased (Figure 34).  
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Figure 34 LGR 1404, 1406 and 1407 decrease chemotaxis of endothelial cells. 
Chemotaxis of HUVECs in the presence or absence of 10 µM of the indicated compounds was 
determined in µ-slides Chemotaxis. A: Quantitative evaluation of accumulated and Euclidean 
distance, velocity and y-forward migration index (n=3, mean ± SEM, * p<0.05, One Way 
ANOVA, Dunnett). B: Representative cell tracking plots of untreated and LGR treated cells.  
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3.2.6 LGR 1404, 1406 and 1407 completely inhibit vessel 
formation in the CAM assay 
The anti-angiogenic potency of the three most effective compounds has been 
evaluated in vitro so far. In order to substantiate these findings, chorioallantoic 
membrane (CAM) assays were performed with LGR 1404, 1406 and 1407, where they 
completely abolished VEGF-induced vessel formation (Figure 35). 
 
Figure 35 LGR 1404, 1406 and 1407 completely inhibit VEGF-induced vessel 
formation in the CAM assay. Cellulose discs with 2.5 ng VEGF / 250 nmol compound or 
2.5 ng VEGF / DMSO as control were placed on the membrane for 24 h. Representative images 
of the stimulated areas of at least three independent experiments are shown.  
3.2.7 Kinase profile of LGR 1406 and 1407 shows preferential 
inhibition of Cdk5 and Cdk2 
We found that LGR 1406 and 1407 were the most potent compounds in the in vitro 
assays. Therefore it was of interest to see which kinases, especially Cdks, are inhibited 
by those compounds. The kinase profiling was performed by ProQinase (Freiburg, 
Germany). For LGR 1404, synthesis, kinase profiling and biological effects on cancer 
cells have recently been published.108  
LGR 1406 and 1407 were tested for their IC50 in a panel of 24 kinases, including the 
Cdk/Cyclin complexes Cdk1/Cyclin B, Cdk2/Cyclin A, Cdk2/Cyclin E, Cdk4/Cyclin D1, 
Cdk5/p25NCK, CDK6/Cyclin D1, CDK7/Cyclin H/MAT1 and Cdk9/Cyclin T. The other 
kinases tested were  
− PTK6 (Protein tyrosine kinase 6, also known as breast tumor kinase, BRK)  
− EGFR (Epidermal growth factor receptor) 
VEGF/
DMSO
LGR 1406LGR 1404 LGR 1407
VEGF/
compound
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− FAK (Focal adhesion kinase) 
− FGFR1 and FGFR2 (Fibroblast growth factor receptor 1 and 2) 
− NLK (Nemo-like kinase) 
− PAK4 (p21 protein (Cdc42/Rac)-activated kinase 4)  
− VEGFR1 and VEGFR2 (Vascular endothelial growth factor receptor 1 and 2) 
− MEK1 (Mitogen-activated protein kinase kinase 1, MAP2K1) 
− ROCK1 (Rho-associated, coiled-coil containing protein kinase 1) 
− RAF1 (v-raf-1 murine leukemia viral oncogene homolog 1),  
− ALK (Anaplastic lymphoma receptor tyrosine kinase) 
− RSK3 (Ribosomal protein S6 kinase, 90kDa, polypeptide 2, RPS6KA2) 
− AURKA (Aurora kinase A) 
− AMPKα1 (protein kinase, AMP-activated, alpha 1 catalytic subunit, PRKAA1) 
The IC50 [M] of LGR 1406 and LGR 1407 for the Cdk/Cyclin complexes are shown in 
Table 27.  
Table 27 Cdk profile of the two most potent substances LGR 1406 and 1407. Both 
compounds show increased selectivity for Cdk2 and Cdk5. 
 
 
Both compounds inhibit mainly Cdk2 and Cdk5, and to some extent Cdk9 and Cdk1. 
Concerning the other tested kinases, FAK, PAK4, RSK3 and Aurora kinase A are 
inhibited by LGR 1406 with an IC50 below 1 x 10-5 M. LGR 1407 only inhibits Aurora 
kinase A (IC50 ≤ 1 x 10-5 M) in addition to the Cdks displayed in Table 27. 
> 10-4 [M]< 10-7
Cdk1/
CycB
Cdk2/
CycA
Cdk2/
CycE
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Cdk9/
CycT
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3.2.8 LGR 1404, 1406 and 1407 reduce lamellipodia formation 
and Rac1 localization to lamellipodia, indicating a Cdk5-
dependent mode of action 
In order to gain insight into the anti-angiogenic action of the three most potent LGR, we 
analyzed their effect on the lamellipodia formation in migrating endothelial cells. It is 
known that Cdk5 inhibition leads to impaired endothelial cell migration via a 
downstream inactivation of Rac1 and resulting in decreased Rac1 localization to the 
leading edge and breakdown of lamellipodia.75 
LGR 1404, 1406 and 1407 significantly diminished the formation of lamellipodia by 
54 % (LGR 1404) to 67 % (LGR 1406) at 10 µM. This can be seen in the corresponding 
images stained for f-actin. The strong decrease in lamellipodia formation was a first 
indication for a Cdk5-dependent mode of action (Figure 36). 
A              B 
 
Figure 36 LGR 1404, 1406 and 1407 significantly decreased lamellipodia formation in 
migrating endothelial cells. Confluent HUVECs were scratched and allowed to migrate in the 
presence of 10 µM or 30 µM of the respective compounds for 8 h. The cells were fixed, stained 
for f-actin and the cells with prominent lamellipodia were counted at the scratch front from 10x 
magnification fluorescence images. A: The graph shows the number of cells with prominent 
lamellipodia per 100 cells at scratch front (n=3, mean ± SEM, * p<0.05, One Way ANOVA, 
Dunnett). B: Representative images of the scratch front (f-actin, 10x magnification).  
 
To substantiate this finding, we examined the localization of Rac1 to the cell front of 
migrating cells. In immunofluorescence stainings we found a decreased Rac1 
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localisation to lamellipodia as displayed in Figure 37. Cortactin served as a marker 
protein for lamellipodia. Again, LGR 1406 and LGR 1407 showed the strongest effects.  
 
Figure 37 The LGR compounds 1404, 1406 and 1407 decreased colocalization of 
Rac1 and cortactin at lamellipodia. Confluent HUVECs were scratched and allowed to 
migrate in the presence of 10 µM of the respective compounds for 8 h. The cells were fixed and 
stained for f-actin (red), cortactin (green) and Rac1 (white) and pictures were taken. 
Representative images out of three experiments are shown (CLSM, 40x magnification). 
3.2.9  LGR 1407 significantly inhibits tumor growth and 
vascularization in a hepatoma xenograft mouse model 
In the in vitro and ex vivo angiogenesis assays, LGR 1406 and LGR 1407 have 
consistently shown the strongest effects, with LGR 1406 being slightly more potent. In 
order to prove the anti-angiogenic and anti-tumor potential of the inhibitors, we 
evaluated the effects of LGR 1407 on tumor growth and vascularization in an in vivo 
tumor model of xenograft hepatocellular carcinoma in SCID mice. LGR 1407 was 
chosen because of its potency and higher selectivity for Cdks in the kinase panel.  
f-actin cortactin Rac1 merge
Co
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LGR 1407 was able to clearly reduce tumor growth after seven days of treatment of the 
xenograft tumors (Figure 38).  
A 
 
B        C 
 
Figure 38 LGR 1407 significantly impairs tumor growth in a hepatoma xenograft 
mouse model. SCID mice with established subcutaneous HUH7 xenograft tumors were treated 
with 30 mg/kg/day LGR 1407 or vehicle for 7 days. A: Images of the tumors after extraction 
(scale: mm) B: Tumor volume during treatment (l x w x d x π/6; Co: n=3, LGR 1407: n=4, mean 
± SEM) C: Tumor weight at end point (Co: n=3, LGR 1407: n=4, mean ± SEM, * p<0.05, t-test). 
 
Figure 38A displays that the treated tumors are not only smaller, but also seem to lack 
sufficient vascularization and blood supply as the tissue appears in part colorless. This 
was further analyzed in CD31 stained tumor sections. In the treated tumors, the 
microvessel density was decreased by 70 % in comparison to the controls (Figure 39).  
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A        B 
 
Figure 39 LGR 1407 significantly decreases microvessel density in the hepatoma 
xenograft tumors. Microvessel density per mm2 tumor tissue was determined after CD31 
staining of tumor sections. A: Microvessel density of Control and LGR 1407 treated tumors (Co: 
n=3, LGR 1407: n=4, mean ± SEM, * p<0.05, t-test). B: Representative images of Control and 
LGR 1407 treated tumor sections (40x magnification, CD31 (red) and hematoxylin 
counterstaining).  
 
200
100
0
CD
31
 
po
s.
 
m
ic
ro
ve
ss
el
s
pe
r 
m
m
2
*
Co
LGR 1407

4 DISCUSSION 
  
80  4  DISCUSSION  
4.1 Elucidation of novel endothelial signaling pathways 
as the basis for future anti-angiogenic therapy 
For the first time, we have demonstrated that regulation of Cdk5 in endothelial cell 
migration differs from the “canonical” pathway reported in neurons and cancer cells. 
This finding is of importance with regard to established anti-angiogenic tumor therapy. 
Therapeutic agents targeting VEGF or its signaling pathways in clinical use show only 
transient benefits. The tumor adapts to anti-angiogenic therapy by switching to 
alternative pro-angiogenic pathways.7 Therefore it is of central interest to elucidate 
novel signaling pathways in tumor angiogenesis to provide the knowledge for future 
therapeutic exploitation. Our group has recently identified Cdk5 as a potential new 
target in endothelial cell migration and angiogenesis. In order to increase our 
understanding of the mechanisms of Cdk5 regulation and to find possible links to 
established angiogenesis signaling pathways, it is necessary to reveal the 
characteristics of Cdk5 activation in endothelial cell migration. New insight into Cdk5 
regulation in endothelial cells might as well lead the way to Cdk5 specific and at the 
same time endothelium-specific inhibitors that target activator-kinase binding. This has 
been established for neurons: the p35-derived CIP109 and p5110 are specific p25/Cdk5 
interaction inhibitors without disturbing p35/Cdk5 activity. 
4.2 Cdk5 regulation in endothelial cell migration exerts 
non-canonical characteristics 
In neurons, p35 and p39, and their truncated forms p25 and p29, respectively, activate 
Cdk5. Additionally, Cdk5 can be regulated by phosphorylation on tyrosine 15 and 
serine 159 (reviewed in Dhavan & Tsai39). Aim of the work was to investigate if Cdk5 
regulation in endothelial cell migration follows the same principles as in neuronal 
migration. 
 
4.2.1 Cdk5 phosphorylation on tyrosine 15 is dispensable in 
endothelial cell migration 
In our work, we concentrated on tyrosine 15 phosphorylation, which is well described 
as activating in neuronal and in non-neuronal cells, and has also been implicated in 
migration and actin dynamics.42, 47, 96 Further phosphorylation sites of Cdk5 on serine 
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159 and threonine 14 have been reported, but their significance in cell signaling 
mechanisms is not clearly defined.62-66 Cdk5 inhibition in migrating endothelial cells 
leads to defects in the actin cytoskeleton and lamellipodia formation, so our hypothesis 
was that Cdk5 may be activated during endothelial cell migration via phosphorylation of 
tyrosine 15.  
Fyn47 and c-abl 46 reportedly phosphorylate Cdk5 at tyrosine 15. Yet, treatment of 
endothelial cells with fyn inhibitor SU6656 or the c-abl inhibitor imatinib did not affect 
migration. Moreover, phosphorylation of Cdk5 during endothelial cell spreading by so 
far unidentified tyrosine kinases is obviously not the case, since Cdk5 tyrosine 15 
phosphorylation was not increased. Finally, a crucial function of phospho-Cdk5Y15 in 
endothelial cell migration was ruled out by overexpression of a non-phosphorylatable 
Cdk5 mutant.  
For Cdk5, it has not conclusively been shown that phosphorylation is essential for full 
activation after binding to its activator. Regarding the structure of activator/Cdk5 
complex, phosphorylation of serine 159 in Cdk5 is not required for reaching the fully 
active conformation.65 If Cdk5 needs to be phosphorylated at tyrosine 15 for full 
activation has not been proven. According to our data, phosphorylation on tyrosine 15 
is not essential for Cdk5 regulation in endothelial cell migration. Recently, a novel 
mode of Cdk5 regulation has been shown: Cdk5 can be activated by S-nitrosylation.111, 
112
 To investigate a regulation of Cdk5 by nitrosylation during endothelial cell migration 
may be of interest, as it has been reported that Cdk5 can inactivate eNOS by 
phosphorylation.105 Moreover, eNOS co-localizes with actin at the cell front during 
HUVEC migration113, and is also connected to Rac1 signaling.114, 115 
4.2.2 p35 and p39 are not central for Cdk5 regulation in 
endothelial cell migration 
Expression of p35 and activation of Cdk5 by p35 has been described in non-neuronal 
cells.54-58 We have shown that p35 and p39 are expressed in endothelial cells as well, 
but reach only a fraction of 3 x 10-3 and 1 x 10-4 of the mRNA expression in brain 
tissue, respectively. In comparison, the protein levels of Cdk5 in endothelial cells are by 
trend lower than in human brain, but not significantly. The extremely low expression 
level of the classical Cdk5 regulators in endothelial cells is in line with the investigations 
of Cho et al.105 In contrast to their findings, we were able to identify p35 on protein level 
in HUVECs and also in HMEC-1. 
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As the expression of p39 was hardly detectable on mRNA level, we focused on the role 
of p35 in endothelial cells, in order to identify its function in migration and angiogenesis. 
To examine the role of p35 during endothelial cell migration, we used spreading cells 
as a model for cytoskeletal activation in comparison to confluent cells. During 
endothelial cell spreading, Cdk5 is targeted to the membrane and p35 expression is 
weakly increased after 45 min and 240 min. As p35 carries a myristoylation which 
targets Cdk5 to the membrane in neuronal cells44, these findings suggested that 1) p35 
might be involved in Cdk5 regulation during migration and 2) p35 may be responsible 
for the membrane localization of Cdk5 during spreading. However, we could not 
consistently detect p35 protein in membrane fractions due to its low amount.  
As Cdk5 inhibition affects growth factor-induced endothelial cell migration75, the 
influence of VEGF, a fundamental stimulus in angiogenesis and endothelial cell 
migration, was investigated. For p35, growth factor (NGF) induced increase in protein 
level has already been shown in neurons.40 p35 protein expression in endothelial cells, 
though, is not induced upon treatment with VEGF, neither with PDGF-B and bFGF. 
This further indicates that p35 is not involved in Cdk5 regulation in endothelial cell 
migration. 
However, we supposed that the degradation of p35 by the proteasome or calpain might 
be involved in Cdk5 activation and redistribution within the cell. Further, stabilization of 
unstable p35 protein by inhibiting degradation could facilitate detection. Indeed, we 
found that p35 protein level is controlled by the proteasome, since treatment with a 
proteasome inhibitor leads to increased protein levels of p35. This effect was utilized to 
detect the p35 siRNA downregulation on protein level. The impact of MG132 on p35 
protein amount indicates a rapid cycle of p35 proteasomal degradation, as has been 
reported for neurons.45 The significance of p35 stabilization for endothelial cell 
migration cannot be determined by MG132 treatment, as this substance strongly 
inhibits NF-κB and this in itself affects endothelial cell migration.116  
The alternative degradation pathway of p35 via the protease calpain leads to the 
cleavage product p25. In neurons, p25 deregulates Cdk5 activity with regard to 
cytosolic localization and prolonged activation. Calpain and the endogenous calpain 
inhibitor calpastatin are active in endothelial cells117 and calpain can be activated 
during VEGF-induced endothelial cell migration.118 However, p25 was not detected in 
endothelial cells, neither after stabilization of the p35 protein by proteasome inhibition, 
which should favor the second degradation pathway. Furthermore, calpain inhibition 
had no effect on endothelial cell migration and did not lead to increased p35 levels. 
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These findings demonstrate that calpain cleavage of p35 to p25 is not involved in the 
regulation of Cdk5 during endothelial migration. 
In p35 siRNA experiments, we could finally rule out a key role of p35 in endothelial cell 
migration. Since it has been shown that p39 is able to counteract the loss of p3553, 
compensation of p35 downregulation by rise of p39 was also excluded.  
The conclusion drawn from the in vitro experiments – p35 is not crucial for endothelial 
cell migration – was substantiated in vivo by our investigations in p35 deficient mice. 
The vascular pattern and the vessel density in p35-/- animals did not differ from those of 
wild type mice. If p35 knockout had affected endothelial cell migration during 
developmental and physiological angiogenesis, obvious defects should have been 
visible in organ vascularization and vessel density, and this is not the case.  
Altogether, the results presented in this study exclude p35 and p39 as key regulators in 
endothelial cell migration. Therefore we, for the first time, have demonstrated that Cdk5 
in endothelial cell migration is not dependent on p35/p25 and p39/p29 as activators.  
4.2.3 p35 is not increased in Cdk5-dependent endothelial 
inflammatory reaction  
Our group has previously proven that additional anti-inflammatory properties of the Cdk 
inhibitor roscovitine result from Cdk5 inhibition in the endothelium.76 This means two 
central functions of the endothelium, migration/angiogenesis and inflammation, are 
regulated by Cdk5. Therefore, the question was, whether p35 might be crucial for Cdk5 
in the endothelial inflammatory response although it has been proven to be extraneous 
in endothelial cell migration. It has already been shown that Cdk5 can be differentially 
modulated by disparate activators in the same cell type.59, 119  
Thus, we investigated the influence of TNF-α treatment on p35 expression in 
endothelial cells, as TNF-α stimulation can increase p35 levels in neuronal and non-
neuronal cells.42, 120 TNF-α had no impact on the amount of p35 protein in endothelial 
cells, which may indicate that p35 has no key role for Cdk5 regulation in inflammatory 
activated endothelium as well. This supports the findings from our investigation of p35 
and p39 in endothelial cell migration, and points out to a specific regulatory mechanism 
for Cdk5 in the endothelium.  
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4.2.4 Evaluation of Cdk5 activity in endothelial cells 
The effect of Cdk5 inhibition on endothelial cell migration is derived from inhibition of 
the kinase activity, since the inhibitor roscovitine blocks the ATP binding-pocket of the 
kinase.74 Furthermore, a dominant negative kinase dead mutant of Cdk5 exerts the 
same effects as Cdk5 loss after siRNA downregulation.75 Thus, it is the activity, and not 
only the presence of Cdk5 that is crucial for endothelial cell migration. 
Measuring the influence of stimuli on Cdk5 kinase activity is of central importance in 
order to explore activators and activating processes of Cdk5. To assess Cdk5 activity, 
we first immunoprecipitated Cdk5, p35, or overexpressed Cdk5-HA. Cdk5-specific 
kinase activity was evaluated by comparison to a negative control, which was obtained 
by addition of Cdk5 inhibitor roscovitine to the kinase reaction, by immunoprecipitation 
with irrelevant or no IgG, or by using HA-untransfected cell lysate, respectively. In all 
settings, the kinase activity in endothelial cells did not significantly differ from the 
negative control. This indicates that endogenous Cdk5 activity is very low in endothelial 
cells and difficult to distinguish from background signal. Methodical issues were ruled 
out by using recombinant Cdk5/p35 kinase to check buffers and antibodies for their 
compatibility with the assay. With p35 immunoprecipitation, it was possible to obtain a 
strong kinase activity from neuronal cell lysate – demonstrating that the assay worked 
– however the signal from the endothelial cells was not distinguishable from 
background. This could now be explained by the finding that p35 does not seem to be 
involved in Cdk5 regulation in endothelial cell migration. After Cdk5-HA overexpression 
and p35-myc co-transfection in order to increase Cdk5 activity and to improve the 
signal/background ratio the signal was still not increased over background. Cdk5 
overexpression alone may lead to an inappropriate activator/kinase ratio. As this could 
not be overcome by p35 co-transfection, our previous findings that p35 is no central 
Cdk5 activator in endothelial cells are further substantiated.  
As Cdk5 activity is reliant on the pairing with its activating subunit, the crucial step in 
the assay is the co-immunoprecipitation of the activator. According to our findings so 
far, Cdk5 activity in endothelial cells is presumably much lower than in neuronal cells. 
In order to get sufficient kinase activity, it is therefore essential to identify the 
endothelial activator of Cdk5 and precipitate the activator with Cdk5, as it is described 
for Cdk5/p35 by Nicolic & Tsai.104  
The challenges that remain for the evaluation of Cdk5 activity in migrating endothelial 
cells are 1) to identify the so far unknown endothelial Cdk5 activator and 2) to optimize 
the kinase assay with the precipitation of activator, in order to obtain sufficient kinase 
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activity, as Cdk5 activity in endothelial cells is supposedly much lower than in neuronal 
cells but central for migration. 
4.2.5 A proteomics approach provides novel insights into 
endothelial Cdk5 signaling 
In literature, few works have investigated the role of Cdk5 in the endothelium; and the 
part of the canonical activators p35/p25 and p39/p29 has not been thoroughly 
examined yet, except by this work. The fact that the central endothelial-related 
processes inflammation and angiogenesis which are regulated by Cdk5 do not depend 
on p35 and p39 raises the question, which up to date unknown activator is responsible 
for Cdk5 activity in endothelial cells. 
We chose a proteomics approach with LC-ESI-MS/MS identification of protein bands 
after Cdk5 immunoprecipitation in order to find novel Cdk5 interacting proteins. This 
approach aims first to identify the activator of Cdk5 in endothelial cell migration. 
Second, up to now unknown Cdk5 substrates upstream from Rac1 could be 
determined in order to reveal the mechanism of Rac1 inactivation by Cdk5 inhibition 
during endothelial cell migration.75 We used two migration-related stimulations for the 
investigations – 45 min spreading and starved/FCS treated cells – in comparison to 
confluent or starved control cells. Three bands were analyzed, as described in the 
results part (list of identified proteins: see Results part, Table 26). The LC-ESI-MS/MS 
identified also Cdk2 and Cdk1 in the band containing Cdk5. This could be either due to 
the about 60% sequence homology of Cdk5 with Cdk1 and Cdk2 respectively27, which 
would lead to overlapping peptides; or owing to partly unspecific antibody binding, as 
the Cdk5 antibody is raised against the whole Cdk5 protein. GBLP (guanine nucleotide-
binding protein subunit beta-2-like 1), also known as RACK1 (Receptor for activated 
protein C kinase 1) belongs to the RACK family of proteins identified as adaptor 
proteins in PKC signaling.121 RACK1 has been shown to regulate VEGFR1-mediated 
endothelial cell migration: RACK1 silencing led to impaired migration, suppressed 
PI3K/AKT cascade activation and inhibited Rac1 activation and membrane ruffling.122 
However, inactivation of Rac1 by Cdk5 inhibition with roscovitine did not affect AKT 
phosphorylation, which suggests an AKT independent pathway. If RACK1 might be the 
link between Cdk5 and Rac1 in endothelial cell migration, still needs to be elucidated. 
RACK1 could be a novel Cdk5 substrate as it carries potential phosphorylation sites for 
Cdk5 (determined with GPS Version 2.1123, 124). 
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Cdk5 plays an important role in the regulation of the actin cytoskeleton125, and it is 
localized to the dense actin network of lamellipodia in endothelial cell migration75. This 
could explain the presence of actin in the immunoprecipitation, although no direct 
interaction of Cdk5 and actin has been reported, only via its neuronal activators p35 
and p39.126, 127 
Various HSP 70 Heat shock proteins co-immunoprecipitated with Cdk5. Heat shock 
proteins are molecular chaperons which guide protein folding and are involved in 
cellular transport. They are upregulated in response to cellular stress but some are also 
constitutively expressed.128 In neurons, Heat shock cognate 71 kDa protein HSP7C can 
bind to, and regulate degradation of Cdk5-hyperphosphorylated tau in neurons; a direct 
Cdk5/HSP7C interaction is not reported.129 The role of HSP 70 in angiogenesis has 
been investigated by Shiota et al.: They showed that global HSP 70 inhibition 
decreased endothelial cell migration, VEGF-induced eNOS phosphorylation and 
angiogenesis in vivo.130 This again might allude to a connection of Cdk5 and eNOS 
during endothelial cell migration. 
The co-IP of lamin A and disks large homolog 4 (or PSD-95), both substrates of Cdk5 
in neurons, proves that our approach of Cdk5-IP and LC-ESI-MS/MS is suitable for 
identifying Cdk5 interacting proteins in endothelial cell migration. Lamin A is a nuclear 
envelope protein, and its phosphorylation by Cdk5 in neuronal cells results in nuclear 
envelope dispersion, which precedes cell death.131 Lamin A can be cleaved during 
endothelial cell apoptosis.132 Further, a lamin A mutant (progerin) is responsible for the 
vascular symptoms in Hutchinson–Gilford progeria syndrome.133 Disks large homolog 4 
(PSD-95) is a post-synaptic density (PSD) protein in glutamatergic synapses, and is 
known as a substrate of Cdk5 in hippocampal neurons.134 Its presence as a synaptic 
protein in endothelial cells is striking and a function in endothelial cells is so far 
unknown. With neurexin and neurogilin two other synaptic proteins have been shown to 
play a role in the vasculature; and the parallels between signaling in nerves and 
vessels very likely exceed the field of guiding cues.135  
Desmoplakin is an intracellular part of desmosomes, tight intercellular junctions, and 
anchors intermediate filaments to these structures. Desmoplakin localizes with VE-
cadherin in HUVECs at tight junctions136 and also is involved in tube formation of 
endothelial cells in vitro.137 In epithelial cells, Cdk5 is involved in the maintenance of 
cell-cell-adhesion.138, 139 The presence of desmoplakin may therefore indicate a role for 
Cdk5 in endothelial barrier function.  
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POTE ankyrin domain family member E (POTE-2) belongs to the primate specific 
POTE family140, which share an ankyrin repeat domain and sequence homology with 
actin. POTE proteins were discovered in prostate, ovary, testis and placenta (POTE= 
prostate ovary testis expressed protein) but have been reported to be overexpressed 
in certain tumors141. POTE proteins are palmitoylated and located at the membrane.142 
Nothing so far is known about their role in the endothelium or a link to Cdk5. 
In order to find the endothelial specific activator a comparison between IPs with 
different antibodies needs to be carried out. It cannot be excluded that the antibody 
interfered with the binding of the activator to Cdk5, as it was not yet possible to 
precipitate a potential candidate for Cdk5 activation. The antibody used was tested in 
the kinase assay with recombinant Cdk5/p35 and does not disturb p35 binding, but the 
binding and amount of the endothelial specific activator might be weaker or lower, 
respectively. Besides p35/p25 and p39/p29, there are reports that Cdk5 can bind to 
several cyclins59,35-38, of which only Cyclin I is able to activate Cdk5.59 Cyclin I is 
expressed in endothelial cells (data not shown), but if it is involved in Cdk5 activation 
needs to be elucidated. Nevertheless, our approach identified promising novel Cdk5 
interacting proteins in endothelial cells. For example RACK1, desmoplakin, lamin A and 
PSD-95 could be worth closer investigations, possibly revealing novel roles of Cdk5 in 
PKC signaling, barrier function, (endothelial cell) apoptosis, and so far unknown 
functions of neuronal synaptic proteins in endothelial cells. 
4.3 Novel LGR inhibitors are potent anti-angiogenic 
compounds and validate Cdk5 as a target 
4.3.1 In vitro potency of LGR compounds is confirmed in the 
CAM assay in vivo 
Our approach to use the effect on endothelial migration as the crucial selection criterion 
resulted in the identification of compounds that were tested further in functional assays 
for their tube formation and directed migration in a chemotactic gradient. Finally, the 
most potent compounds LGR 1404, 1406 and 1407 proved their anti-angiogenic 
potency in CAM-assays, where they completely inhibited VEGF-induced vessel 
formation. We have identified three potent novel roscovitine derivatives that display 
increased anti-angiogenic activity in comparison to their mother substance. 
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4.3.2 Kinase data and Cdk5-dependent mode of action of 
LGR 1404, 1406 and 1407 
Roscovitine inhibits several Cdks, mainly Cdk1, Cdk2, Cdk5, Cdk7 and Cdk9. The 
selectivity data depend on the kinase panel referred to.74, 108, 143, 144 LGR 1407 is equally 
potent in inhibition of Cdk2 and Cdk5, and inhibits Cdk1 and Cdk9 to some extent. 
LGR 1406 is by one order of magnitude more selective towards Cdk5 and Cdk2 in 
comparison to Cdk1 and Cdk9. Both compounds inhibited preferably Cdks in our 
kinase panel, with LGR 1407 showing a higher Cdk selectivity. Comparing the two 
most powerful compounds LGR 1406 and 1407, the lower IC50 for Cdk5 and the higher 
selectivity for Cdk5 (and Cdk2) of LGR 1406 mirror the effect in the angiogenesis 
assays. LGR 1407 is more selective towards Cdk5 in comparison to LGR 1404, which 
mainly inhibits Cdk2 (IC50 for Cdk2 0.22 µM, for Cdk5 0.94 µM according to Jorda et 
al.108). This is probably the reason why LGR 1404 is the least potent anti-angiogenic 
compound of the three with regard to the in vitro data. Determining the effect of 
LGR 1404, 1406 and 1407 on lamellipodia formation and Rac1 localization, we suggest 
that their mode of action is the potent inhibition of Cdk5 and not Cdk2. The lower 
selectivity of LGR 1404 for Cdk5 becomes also apparent in the lamellipodia 
quantification and the Rac1/lamellipodia immunofluorescence images: the disruption of 
lamellipodia and the effect on Rac1 is not that prominent as with LGR 1406 and 
LGR 1407.  
4.3.3 Structure and anti-angiogenic potency of the LGR  
In order to optimize the structure of the Cdk inhibitors for optimal anti-angiogenic 
potential, the relation of structure changes and anti-angiogenic effect is of interest. For 
the LGR compounds as roscovitine derivatives, the structure was modified in three 
points:  
 
1 - Changing the purine scaffold to a pyrazolo[4,3-d]pyrimidine  
In general, the change of the scaffold led to a higher anti-angiogenic potency of the 
substances. All substances chosen for further evaluation after the migration assay 
share the pyrazolo[4,3-d]pyrimidine scaffold. Direct comparison of the potency of 
roscovitine and its pyrazolo[4,3-d]pyrimidine bioisoster, LGR 1404, substantiates this 
observation. The only compound tested with a purine scaffold, LGR 1730, showed the 
weakest effect on proliferation and only a minor impact on migration.  
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2 - ortho-amino function in the aminobenzyl group at C6 (purine) or C7 (pyrazolo[4,3-
d]pyrimidine) 
The presence of an amino group rather seems to decrease the anti-angiogenic 
potential of the compounds. The compounds LGR 1430 and LGR 1492 differ from 
LGR 1406 and LGR 1404, respectively, only in the presence of the amino function, and 
show both weaker effects. This is especially obvious in the comparison of LGR 1406 
and LGR 1430 as LGR 1406 was the most potent compound in the assays, whereas 
LGR 1430 showed no detectable effect on migration at 30 µM (data not shown).  
 
3 - Variation of the side chain at C2 (purine) or C5 (pyrazolo[4,3-d]pyrimidine) 
Evaluating the impact of different side chains on the anti-angiogenic effect is difficult as 
the compounds differ from roscovitine in more than one structural property and no 
direct comparison is possible. By trend, a bulky side chain like the substituted sec-
butyl- (e.g. LGR 1404) or cyclohexyl- (e.g. LGR 1406) groups seem to increase anti-
angiogenic potency. 
4.3.4 Novel Cdk5 inhibitors validate Cdk5 as an anti-angiogenic 
target in vitro and in the LGR 1407 tumor xenograft 
For further evaluation of Cdk5 as a target in angiogenesis, novel inhibitors with 
increased Cdk5 selectivity need to be synthesized and examined for their anti-
angiogenic potential. We have demonstrated that LGR 1404, 1406 and 1407 are able 
to potently inhibit angiogenesis in vitro via a Cdk5-dependent mechanism and show a 
higher potency and selectivity for Cdk5 in comparison to the established Cdk5 inhibitor 
roscovitine. Additionally, LGR 1407 was well tolerated in the in vivo mouse model and 
led to a clear decrease in tumor vascularization and tumor growth. The conclusions we 
can draw from this experiment are clear: On the one hand, with LGR 1407 we have a 
potent anti-tumor agent displaying low toxicity in vivo. On the other hand, for the first 
time we have shown the efficacy of a Cdk5 inhibitor on tumor angiogenesis in vivo. 
This further validates Cdk5 as a promising target in angiogenesis and the therapeutic 
potential of Cdk5 inhibitors.  
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4.4 Conclusion and future aspects 
4.4.1 Cdk5 upstream regulation in endothelial cells  
This work provides first insight into Cdk5 upstream regulation in endothelial cells, which 
we have for the first time proven to substantially differ from the “canonical” pathway via 
p35/p25 and p39/p29 and tyrosine 15 phosphorylation. A goal for future research is the 
identification of the so far unknown endothelial specific Cdk5 activator(s). A possible 
candidate for further investigations is Cyclin I, which is expressed in HUVECs and 
HMEC-1, and has been shown to activate Cdk5. A useful approach for further research 
is provided by the Cdk5 immunoprecipitation and LC-ESI-MS/MS: on the one hand it 
showed that neuronal substrates of Cdk5 are probably also involved in endothelial cell 
signaling, and on the other hand revealed potential novel Cdk5 interacting partners, 
with RACK1 as a possible link to Rac1 activation.   
4.4.2 Cdk inhibitors with higher potency and selectivity to Cdk5  
The concept of Cdk5 inhibition to target angiogenesis has recently been introduced by 
our group. In this study, novel roscovitine derivatives were tested in order to find 
effective and non-toxic small molecule inhibitors for a possible therapeutic application. 
Three potent compounds were identified: LGR 1404, 1406 and 1407 strongly inhibit 
angiogenesis in vitro and in vivo. Their impact on Cdk5 parallels the efficacy in the 
angiogenesis assays which supports the strategy of Cdk5 inhibition as a powerful new 
approach in anti-angiogenic therapy. Moreover, for the first time the efficacy of a Cdk5 
inhibitor on tumor angiogenesis in a HCC xenograft mouse model has been 
demonstrated with the compound LGR 1407. For the further development of anti-
angiogenic roscovitine derivatives, comparison of the structures of the tested LGR 
inhibitors shows a positive correlation to anti-angiogenic potency for the pyrazolo[4,3-
d]pyrimidine scaffold and a negative correlation for an additional amino function in the 
benzyl group. 
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The discovery, characterization and validation of novel targets in angiogenesis is of 
central interest, as clinical use of anti-angiogenic drugs in anticancer therapy has 
shown that in many cases resistance and sustained tumor growth occur in response to 
blockade of VEGF-induced angiogenesis by a shift towards alternative angiogenic 
pathways.  
Cyclin-dependent kinase inhibitors, which were actually designed as anti-proliferative 
drugs affecting the cell cycle of the limitless proliferating tumor cells, exert anti-
angiogenic properties as well. The atypical cyclin-dependent kinase Cdk5 has recently 
been identified as a potential target protein for the anti-angiogenic effects. Cdk5 
inhibition leads – via Rac1 inactivation – to actin disorganization, lamellipodia 
breakdown and consequently to a decrease of endothelial cell migration.75  
In the first part of the presented study, the question was addressed if Cdk5 is regulated 
during endothelial cell migration by the known mechanisms: via its neuronal non-cyclin 
activators p35 or p39, or by tyrosine 15 phosphorylation.  
The activating tyrosine 15 phosphorylation of Cdk5 was found to be dispensable for 
Cdk5 regulation in endothelial cell migration.  
A low amount of p35 is expressed in endothelial cells on mRNA and protein level, 
whereas p39 mRNA is at the limit of detection. p25, the calpain cleavage product of 
p35 and alternative Cdk5 activator, though, is not present in endothelial cells. 
Downregulation of p35 does not affect endothelial cell migration and does not lead to a 
compensatory upregulation of p39. In vivo, p35 deficient mice do not display vascular 
aberrations. These findings exclude p35 as a central regulator of endothelial cell 
migration during angiogenesis. Cdk5 kinase activity in endothelial cells is very likely 
independent of p35 as well. There was also no strong hint for a prominent role of p35 in 
TNF-α induced inflammatory reaction of endothelial cells, a second major process in 
the endothelium under the control of Cdk5. Mass spectrometric identification of proteins 
co-immunoprecipitated with Cdk5 revealed novel potential Cdk5 interactants in 
endothelial cells. If Cyclin I, an alternative Cdk5 activator which is also expressed in 
endothelial cells, is involved in Cdk5 regulation in endothelial cells still needs to be 
elucidated.  
The second part of the study dealt with the evaluation of prospective anti-angiogenic 
Cdk inhibitors, paying particular consideration on their potency to inhibit Cdk5. Eight 
novel roscovitine derivatives were assessed in vitro for their impact on endothelial 
proliferation, migration, chemotaxis and tube formation. The three most potent 
compounds LGR 1404, 1406 and 1407 were selected and proved their anti-angiogenic 
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potency in chorioallantoic membrane assays in vivo. LGR 1406 and LGR 1407 showed 
preferred inhibition of Cdk5 (and Cdk2), whereas the slightly less effective LGR 1404 
inhibited Cdk2 rather than Cdk5. Immunostainings demonstrated that the three LGR 
compounds affect endothelial cell migration by lamellipodia breakdown and cortactin 
and Rac1 mislocalization, which suggests a Cdk5-dependent mode of action. LGR 
1407 decreased tumor growth and angiogenesis in a hepatocellular carcinoma 
xenograft in SCID mice. For the future development of anti-angiogenic compounds, 
comparison of the structures of the tested LGR inhibitors shows a positive correlation 
to anti-angiogenic potency for the pyrazolo[4,3-d]pyrimidine scaffold and a negative 
correlation for an additional amino function in the benzyl group.  
 
From these findings, we conclude that regulation of Cdk5 in endothelial cells follows an 
alternative mechanism different from the canonical pathway via p35 and p39 described 
in neurons. Moreover, we present a promising approach to identify novel Cdk5 
interacting proteins and suggest Cyclin I as a candidate for upcoming investigations. 
Using novel potent Cdk inhibitors, our results further support the idea of Cdk5 inhibition 
as a future approach for anti-angiogenic therapy, highlighting the compound LGR 1407 
as a potent inhibitor of tumor growth and vascularization.  
 

6 REFERENCES 
  
96  6  REFERENCES  
1. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. 
Circ Res. Mar 30 2007;100(6):782-794. 
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. Jan 7 2000;100(1):57-
70. 
3. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. 
Oncogene. Sep 29 2003;22(42):6549-6556. 
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell. Aug 9 1996;86(3):353-364. 
5. Zeneca A. AstraZeneca announces trade name CAPRELSA® for vandetanib. 
2011; http://www.astrazeneca-us.com/about-astrazeneca-
us/newsroom/all/12379191?itemId=12379191. Accessed September 20, 2011, 
2011. 
6. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of 
angiogenesis. Nature. May 19 2011;473(7347):298-307. 
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev 
Cancer. Aug 2008;8(8):592-603. 
8. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling 
metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. Mar 3 
2009;15(3):167-170. 
9. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant 
progression of tumors to increased local invasion and distant metastasis. Cancer 
Cell. Mar 3 2009;15(3):220-231. 
10. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during 
blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011;12(9):551-564. 
11. Fischer C SM, Carmeliet P. Principles and Therapeutic Implications of 
Angiogenesis, Vasculogenesis and Arteriogenesis. In: Moncada S HA, ed. The 
Vascular Endothelium II. Berlin Heidelberg: Springer-Verlag; 2006. 
12. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends 
Biochem Sci. Nov 2005;30(11):630-641. 
13. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. 
Nat Rev Cancer. Mar 2009;9(3):153-166. 
14. Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell. Apr 16 
2004;117(2):239-251. 
15. Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and 
transcription. J Cell Sci. Nov 15 2005;118(Pt 22):5171-5180. 
16. Pinhero R, Liaw P, Bertens K, Yankulov K. Three cyclin-dependent kinases 
preferentially phosphorylate different parts of the C-terminal domain of the large 
subunit of RNA polymerase II. Eur J Biochem. Mar 2004;271(5):1004-1014. 
6  REFERENCES 97 
17. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-
containing mediator complexes. Nature. Sep 7 2000;407(6800):102-106. 
18. Fu TJ, Peng J, Lee G, Price DH, Flores O. Cyclin K functions as a CDK9 
regulatory subunit and participates in RNA polymerase II transcription. J Biol 
Chem. Dec 3 1999;274(49):34527-34530. 
19. Garriga J, Grana X. Cellular control of gene expression by T-type cyclin/CDK9 
complexes. Gene. Aug 4 2004;337:15-23. 
20. Yokoyama H, Gruss OJ, Rybina S, et al. Cdk11 is a RanGTP-dependent 
microtubule stabilization factor that regulates spindle assembly rate. J Cell Biol. 
Mar 10 2008;180(5):867-875. 
21. Wilker EW, van Vugt MA, Artim SA, et al. 14-3-3sigma controls mitotic translation 
to facilitate cytokinesis. Nature. Mar 15 2007;446(7133):329-332. 
22. Petretti C, Savoian M, Montembault E, Glover DM, Prigent C, Giet R. The 
PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar 
spindle formation. EMBO Rep. Apr 2006;7(4):418-424. 
23. Chen HH, Wong YH, Geneviere AM, Fann MJ. CDK13/CDC2L5 interacts with L-
type cyclins and regulates alternative splicing. Biochem Biophys Res Commun. 
Mar 16 2007;354(3):735-740. 
24. Chen HH, Wang YC, Fann MJ. Identification and characterization of the 
CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol. 
Apr 2006;26(7):2736-2745. 
25. Tassan JP, Jaquenoud M, Fry AM, Frutiger S, Hughes GJ, Nigg EA. In vitro 
assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 
36 kDa RING finger protein. EMBO J. Nov 15 1995;14(22):5608-5617. 
26. Larochelle S, Merrick KA, Terret ME, et al. Requirements for Cdk7 in the 
assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics 
in human cells. Mol Cell. Mar 23 2007;25(6):839-850. 
27. Hellmich MR, Pant HC, Wada E, Battey JF. Neuronal cdc2-like kinase: a cdc2-
related protein kinase with predominantly neuronal expression. Proc Natl Acad 
Sci U S A. Nov 15 1992;89(22):10867-10871. 
28. Songyang Z, Lu KP, Kwon YT, et al. A structural basis for substrate specificities 
of protein Ser/Thr kinases: primary sequence preference of casein kinases I and 
II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and 
Erk1. Mol Cell Biol. Nov 1996;16(11):6486-6493. 
29. Ohshima T, Ward JM, Huh CG, et al. Targeted disruption of the cyclin-dependent 
kinase 5 gene results in abnormal corticogenesis, neuronal pathology and 
perinatal death. Proc Natl Acad Sci U S A. Oct 1 1996;93(20):11173-11178. 
30. Smith DS, Tsai LH. Cdk5 behind the wheel: a role in trafficking and transport? 
Trends Cell Biol. Jan 2002;12(1):28-36. 
98  6  REFERENCES  
31. Su SC, Tsai LH. Cyclin-Dependent Kinases in Brain Development and Disease. 
Annu Rev Cell Dev Biol. Oct 29 2010. 
32. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 
Conversion of p35 to p25 deregulates Cdk5 activity and promotes 
neurodegeneration. Nature. Dec 9 1999;402(6762):615-622. 
33. Liebl J, Furst R, Vollmar AM, Zahler S. Twice switched at birth: Cell cycle-
independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in 
non-neuronal cells. Cell Signal. Nov 2011;23(11):1698-1707. 
34. Rosales JL, Lee KY. Extraneuronal roles of cyclin-dependent kinase 5. 
Bioessays. Oct 2006;28(10):1023-1034. 
35. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein 
kinases and the DNA replication and repair factor PCNA. Cell. Oct 30 
1992;71(3):505-514. 
36. Guidato S, McLoughlin DM, Grierson AJ, Miller CC. Cyclin D2 interacts with cdk-
5 and modulates cellular cdk-5/p35 activity. J Neurochem. Jan 1998;70(1):335-
340. 
37. Miyajima M, Nornes HO, Neuman T. Cyclin E is expressed in neurons and forms 
complexes with cdk5. Neuroreport. May 30 1995;6(8):1130-1132. 
38. Kanaoka Y, Kimura SH, Okazaki I, Ikeda M, Nojima H. GAK: a cyclin G 
associated kinase contains a tensin/auxilin-like domain. FEBS Lett. Jan 27 
1997;402(1):73-80. 
39. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol. Oct 
2001;2(10):749-759. 
40. Harada T, Morooka T, Ogawa S, Nishida E. ERK induces p35, a neuron-specific 
activator of Cdk5, through induction of Egr1. Nat Cell Biol. May 2001;3(5):453-
459. 
41. Utreras E, Futatsugi A, Rudrabhatla P, et al. Tumor necrosis factor-alpha 
regulates cyclin-dependent kinase 5 activity during pain signaling through 
transcriptional activation of p35. J Biol Chem. Jan 23 2009;284(4):2275-2284. 
42. Nohara A, Okada S, Ohshima K, Pessin JE, Mori M. CDK5 is a key molecule in 
TNF-{alpha} induced insulin resistance. J Biol Chem. Aug 3 2011. 
43. Song JH, Wang CX, Song DK, Wang P, Shuaib A, Hao C. Interferon gamma 
induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-
dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem. Apr 
1 2005;280(13):12896-12901. 
44. Asada A, Yamamoto N, Gohda M, Saito T, Hayashi N, Hisanaga S. 
Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear 
localization of active cyclin-dependent kinase 5 complexes. J Neurochem. Aug 
2008;106(3):1325-1336. 
6  REFERENCES 99 
45. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific 
activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-
proteasome pathway. J Biol Chem. Sep 11 1998;273(37):24057-24064. 
46. Zukerberg LR, Patrick GN, Nikolic M, et al. Cables links Cdk5 and c-Abl and 
facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite 
outgrowth. Neuron. Jun 2000;26(3):633-646. 
47. Miyamoto Y, Yamauchi J, Tanoue A. Cdk5 phosphorylation of WAVE2 regulates 
oligodendrocyte precursor cell migration through nonreceptor tyrosine kinase 
Fyn. J Neurosci. Aug 13 2008;28(33):8326-8337. 
48. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S. Calpain-
dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to 
p25. J Biol Chem. Jun 2 2000;275(22):17166-17172. 
49. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces 
cleavage of p35 to p25 by calpain. Nature. May 18 2000;405(6784):360-364. 
50. Patzke H, Tsai LH. Calpain-mediated cleavage of the cyclin-dependent kinase-5 
activator p39 to p29. J Biol Chem. Mar 8 2002;277(10):8054-8060. 
51. Yamada M, Saito T, Sato Y, et al. Cdk5--p39 is a labile complex with the similar 
substrate specificity to Cdk5--p35. J Neurochem. Sep 2007;102(5):1477-1487. 
52. Hisanaga S, Saito T. The regulation of cyclin-dependent kinase 5 activity through 
the metabolism of p35 or p39 Cdk5 activator. Neurosignals. Sep-Oct 2003;12(4-
5):221-229. 
53. Ko J, Humbert S, Bronson RT, et al. p35 and p39 are essential for cyclin-
dependent kinase 5 function during neurodevelopment. J Neurosci. Sep 1 
2001;21(17):6758-6771. 
54. Griffin SV, Hiromura K, Pippin J, et al. Cyclin-dependent kinase 5 is a regulator of 
podocyte differentiation, proliferation, and morphology. Am J Pathol. Oct 
2004;165(4):1175-1185. 
55. Okada S, Yamada E, Saito T, et al. CDK5-dependent phosphorylation of the Rho 
family GTPase TC10(alpha) regulates insulin-stimulated GLUT4 translocation. J 
Biol Chem. Dec 19 2008;283(51):35455-35463. 
56. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxin-triggered prostate 
cancer cell apoptosis. J Biol Chem. Jul 9 2004;279(28):29302-29307. 
57. Feldmann G, Mishra A, Hong SM, et al. Inhibiting the cyclin-dependent kinase 
CDK5 blocks pancreatic cancer formation and progression through the 
suppression of Ras-Ral signaling. Cancer Res. Jun 1 2010;70(11):4460-4469. 
58. Ubeda M, Kemp DM, Habener JF. Glucose-induced expression of the cyclin-
dependent protein kinase 5 activator p35 involved in Alzheimer's disease 
regulates insulin gene transcription in pancreatic beta-cells. Endocrinology. Jun 
2004;145(6):3023-3031. 
100  6  REFERENCES  
59. Brinkkoetter PT, Olivier P, Wu JS, et al. Cyclin I activates Cdk5 and regulates 
expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest. Sep 1 
2009. 
60. Kawauchi T, Chihama K, Nabeshima Y, Hoshino M. Cdk5 phosphorylates and 
stabilizes p27kip1 contributing to actin organization and cortical neuronal 
migration. Nat Cell Biol. Jan 2006;8(1):17-26. 
61. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates 
cell migration through the regulation of RhoA activation. Genes Dev. Apr 15 
2004;18(8):862-876. 
62. Sharma P, Sharma M, Amin ND, Albers RW, Pant HC. Regulation of cyclin-
dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci U S 
A. Sep 28 1999;96(20):11156-11160. 
63. Rosales J, Han B, Lee KY. Cdk7 functions as a cdk5 activating kinase in brain. 
Cell Physiol Biochem. 2003;13(5):285-296. 
64. Poon RY, Lew J, Hunter T. Identification of functional domains in the neuronal 
Cdk5 activator protein. J Biol Chem. Feb 28 1997;272(9):5703-5708. 
65. Tarricone C, Dhavan R, Peng J, Areces LB, Tsai LH, Musacchio A. Structure and 
regulation of the CDK5-p25(nck5a) complex. Mol Cell. Sep 2001;8(3):657-669. 
66. Matsuura I, Wang JH. Demonstration of cyclin-dependent kinase inhibitory 
serine/threonine kinase in bovine thymus. J Biol Chem. Mar 8 
1996;271(10):5443-5450. 
67. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and 
Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67-108. 
68. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. 
Nat Rev Cancer. Dec 2001;1(3):222-231. 
69. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. 
Oncogene. Sep 29 2003;22(42):6609-6620. 
70. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer 
therapy: what is next? Trends Pharmacol Sci. Jan 2008;29(1):16-21. 
71. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From 
starfish oocytes to clinical trials. Acc Chem Res. Jun 2003;36(6):417-425. 
72. Guzi T. CYC-202 Cyclacel. Curr Opin Investig Drugs. Dec 2004;5(12):1311-1318. 
73. Aldoss IT, Tashi T, Ganti AK. Seliciclib in malignancies. Expert Opin Investig 
Drugs. Dec 2009;18(12):1957-1965. 
74. Meijer L, Bettayeb K, Galons H. (R)-Roscovitine (CYC202, Seliciclib). In: Smith 
PJ, Yue EW, eds. Inhibitors of cyclin dependent kinases as anti-tumor agents: 
CRC Press Taylor & Francis Group; 2006. 
6  REFERENCES 101 
75. Liebl J, Weitensteiner SB, Vereb G, et al. Cyclin-dependent kinase 5 regulates 
endothelial cell migration and angiogenesis. J Biol Chem. Nov 12 
2010;285(46):35932-35943. 
76. Berberich N, Uhl B, Joore J, et al. Roscovitine blocks leukocyte extravasation by 
inhibition of cyclin-dependent kinases 5 and 9. Br J Pharmacol. Jul 
2011;163(5):1086-1098. 
77. Strock CJ, Park JI, Nakakura EK, et al. Cyclin-dependent kinase 5 activity 
controls cell motility and metastatic potential of prostate cancer cells. Cancer 
Res. Aug 1 2006;66(15):7509-7515. 
78. Tanaka T, Serneo FF, Tseng HC, Kulkarni AB, Tsai LH, Gleeson JG. Cdk5 
phosphorylation of doublecortin ser297 regulates its effect on neuronal migration. 
Neuron. Jan 22 2004;41(2):215-227. 
79. Lilja L, Yang SN, Webb DL, Juntti-Berggren L, Berggren PO, Bark C. Cyclin-
dependent kinase 5 promotes insulin exocytosis. J Biol Chem. Sep 7 
2001;276(36):34199-34205. 
80. Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecule alpha v integrin 
antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. 
Anticancer Res. Mar-Apr 1999;19(2A):959-968. 
81. Zahler S, Liebl J, Furst R, Vollmar AM. Anti-angiogenic potential of small 
molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis. Sep 
2010;13(3):239-249. 
82. Krystof V, Rarova L, Liebl J, et al. The selective P-TEFb inhibitor CAN508 targets 
angiogenesis. Eur J Med Chem. Sep 2011;46(9):4289-4294. 
83. Neuhof C, Fabiunke V, Deibele K, et al. Reduction of myocardial infarction by 
calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts. Biol 
Chem. Nov 2004;385(11):1077-1082. 
84. Blake RA, Broome MA, Liu X, et al. SU6656, a selective src family kinase 
inhibitor, used to probe growth factor signaling. Mol Cell Biol. Dec 
2000;20(23):9018-9027. 
85. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an 
immortalized human microvascular endothelial cell line. J Invest Dermatol. Dec 
1992;99(6):683-690. 
86. Bouis D, Hospers GA, Meijer C, Molema G, Mulder NH. Endothelium in vitro: a 
review of human vascular endothelial cell lines for blood vessel-related research. 
Angiogenesis. 2001;4(2):91-102. 
87. Li H, Oehrlein SA, Wallerath T, et al. Activation of protein kinase C alpha and/or 
epsilon enhances transcription of the human endothelial nitric oxide synthase 
gene. Mol Pharmacol. Apr 1998;53(4):630-637. 
102  6  REFERENCES  
88. Menn B, Bach S, Blevins TL, Campbell M, Meijer L, Timsit S. Delayed treatment 
with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 
activity increase in animal stroke models. PLoS One. 2010;5(8):e12117. 
89. Tsai LH, Takahashi T, Caviness VS, Jr., Harlow E. Activity and expression 
pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. 
Development. Dec 1993;119(4):1029-1040. 
90. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using 
bicinchoninic acid. Anal Biochem. Oct 1985;150(1):76-85. 
91. Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 
May 7 1976;72:248-254. 
92. Laemmli UK. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature. Aug 15 1970;227(5259):680-685. 
93. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 
Proc Natl Acad Sci U S A. Sep 1979;76(9):4350-4354. 
94. Kurien BT, Scofield RH. Protein blotting: a review. J Immunol Methods. Mar 1 
2003;274(1-2):1-15. 
95. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-
PCR. Nucleic Acids Res. May 1 2001;29(9):e45. 
96. Qiao F, Gao CY, Tripathi BK, Zelenka PS. Distinct functions of Cdk5(Y15) 
phosphorylation and Cdk5 activity in stress fiber formation and organization. Exp 
Cell Res. Nov 15 2008;314(19):3542-3550. 
97. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell 
cycle control. Science. Dec 24 1993;262(5142):2050-2054. 
98. Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH. Mice lacking p35, a 
neuronal specific activator of Cdk5, display cortical lamination defects, seizures, 
and adult lethality. Neuron. Jan 1997;18(1):29-42. 
99. Zengel P, Nguyen-Hoang A, Schildhammer C, Zantl R, Kahl V, Horn E. mu-Slide 
Chemotaxis: A new chamber for long-term chemotaxis studies. BMC Cell Biol. 
2011;12(1):21. 
100. Gao CY, Zakeri Z, Zhu Y, He H, Zelenka PS. Expression of Cdk5, p35, and 
Cdk5-associated kinase activity in the developing rat lens. Dev Genet. 
1997;20(3):267-275. 
101. Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of 
endothelial cell proliferation/apoptosis is associated with the down-regulation of 
cell cycle regulatory protein cdk5. J Cell Biochem. Feb 1 2004;91(2):398-409. 
102. Altucci L, Addeo R, Cicatiello L, et al. 17beta-Estradiol induces cyclin D1 gene 
transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation 
6  REFERENCES 103 
during mitogenic stimulation of G(1)-arrested human breast cancer cells. 
Oncogene. Jun 6 1996;12(11):2315-2324. 
103. Saito T, Onuki R, Fujita Y, et al. Developmental regulation of the proteolysis of 
the p35 cyclin-dependent kinase 5 activator by phosphorylation. J Neurosci. Feb 
15 2003;23(4):1189-1197. 
104. Nikolic M, Tsai LH. Activity and regulation of p35/Cdk5 kinase complex. Methods 
Enzymol. 2000;325:200-213. 
105. Cho DH, Seo J, Park JH, et al. Cyclin-dependent kinase 5 phosphorylates 
endothelial nitric oxide synthase at serine 116. Hypertension. Feb 
2010;55(2):345-352. 
106. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of 
roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, 
cdk2 and cdk5. Eur J Biochem. Jan 15 1997;243(1-2):527-536. 
107. Wang D, de la Fuente C, Deng L, et al. Inhibition of human immunodeficiency 
virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol. 
Aug 2001;75(16):7266-7279. 
108. Jorda R, Havlicek L, McNae IW, et al. Pyrazolo[4,3-d]pyrimidine bioisostere of 
roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases 
with antiproliferative activity. J Med Chem. Apr 28 2011;54(8):2980-2993. 
109. Zheng YL, Li BS, Amin ND, Albers W, Pant HC. A peptide derived from cyclin-
dependent kinase activator (p35) specifically inhibits Cdk5 activity and 
phosphorylation of tau protein in transfected cells. Eur J Biochem. Sep 
2002;269(18):4427-4434. 
110. Zheng YL, Amin ND, Hu YF, et al. A 24-residue peptide (p5), derived from p35, 
the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau 
hyperphosphorylation. J Biol Chem. Oct 29 2010;285(44):34202-34212. 
111. Zhang P, Yu PC, Tsang AH, et al. S-nitrosylation of cyclin-dependent kinase 5 
(cdk5) regulates its kinase activity and dendrite growth during neuronal 
development. J Neurosci. Oct 27 2010;30(43):14366-14370. 
112. Qu J, Nakamura T, Cao G, Holland EA, McKercher SR, Lipton SA. S-
Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by 
{beta}-amyloid peptide. Proc Natl Acad Sci U S A. Aug 15 2011. 
113. Bulotta S, Cerullo A, Barsacchi R, et al. Endothelial nitric oxide synthase is 
segregated from caveolin-1 and localizes to the leading edge of migrating cells. 
Exp Cell Res. Apr 1 2006;312(6):877-889. 
114. Rao GK, Bender JR. Rac, PAK, and eNOS ACTion. Circ Res. Aug 15 
2008;103(4):328-330. 
115. Sawada N, Salomone S, Kim HH, Kwiatkowski DJ, Liao JK. Regulation of 
endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res. 
Aug 15 2008;103(4):360-368. 
104  6  REFERENCES  
116. Park SY, Yi EY, Jung M, Lee YM, Kim YJ. Ethyl pyruvate, an anti-inflammatory 
agent, inhibits tumor angiogenesis through inhibition of the NF-kappaB signaling 
pathway. Cancer Lett. Apr 28 2011;303(2):150-154. 
117. Fujitani K, Kambayashi J, Sakon M, et al. Identification of mu-, m-calpains and 
calpastatin and capture of mu-calpain activation in endothelial cells. J Cell 
Biochem. Aug 1 1997;66(2):197-209. 
118. Su Y, Cui Z, Li Z, Block ER. Calpain-2 regulation of VEGF-mediated 
angiogenesis. FASEB J. Jul 2006;20(9):1443-1451. 
119. Brinkkoetter PT, Wu JS, Ohse T, et al. p35, the non-cyclin activator of Cdk5, 
protects podocytes against apoptosis in vitro and in vivo. Kidney Int. Apr 
2010;77(8):690-699. 
120. Utreras E, Futatsugi A, Pareek TK, Kulkarni AB. Molecular Roles of Cdk5 in Pain 
Signaling. Drug Discov Today Ther Strateg. Sep 2009;6(3):105-111. 
121. Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated 
signal transduction. Oncogene. Oct 1 2001;20(44):6339-6347. 
122. Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. RACK1 
regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt 
pathway. J Biol Chem. Mar 18 2011;286(11):9097-9106. 
123. GPS 2.1 [computer program]: CUCKOO Workgroup, Hefei National Laboratory 
for Physical Sciences at Microscale and School of Life Sciences, University of 
Science & Technology of China, Hefei, Anhui 230027, China; 2011. 
124. Xue Y, Ren J, Gao X, Jin C, Wen L, Yao X. GPS 2.0, a tool to predict kinase-
specific phosphorylation sites in hierarchy. Mol Cell Proteomics. Sep 
2008;7(9):1598-1608. 
125. Smith D. Cdk5 in neuroskeletal dynamics. Neurosignals. Sep-Oct 2003;12(4-
5):239-251. 
126. He L, Zhang Z, Yu Y, Ahmed S, Cheung NS, Qi RZ. The neuronal p35 activator 
of Cdk5 is a novel F-actin binding and bundling protein. Cell Mol Life Sci. May 
2011;68(9):1633-1643. 
127. Humbert S, Dhavan R, Tsai L. p39 activates cdk5 in neurons, and is associated 
with the actin cytoskeleton. J Cell Sci. Mar 2000;113 ( Pt 6):975-983. 
128. Meimaridou E, Gooljar SB, Chapple JP. From hatching to dispatching: the 
multiple cellular roles of the Hsp70 molecular chaperone machinery. J Mol 
Endocrinol. Jan 2009;42(1):1-9. 
129. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates 
phosphorylated tau and enhances cell survival. J Biol Chem. Feb 6 
2004;279(6):4869-4876. 
6  REFERENCES 105 
130. Shiota M, Kusakabe H, Izumi Y, et al. Heat shock cognate protein 70 is essential 
for Akt signaling in endothelial function. Arterioscler Thromb Vasc Biol. Mar 
2010;30(3):491-497. 
131. Chang KH, Multani PS, Sun KH, et al. Nuclear envelope dispersion triggered by 
deregulated Cdk5 precedes neuronal death. Mol Biol Cell. May 2011;22(9):1452-
1462. 
132. Ohta T, Eguchi R, Suzuki A, Miyakaze S, Ayuzawa R, Kaji K. Hypoxia-induced 
apoptosis and tube breakdown are regulated by p38 MAPK but not by caspase 
cascade in an in vitro capillary model composed of human endothelial cells. J 
Cell Physiol. Jun 2007;211(3):673-681. 
133. McClintock D, Gordon LB, Djabali K. Hutchinson-Gilford progeria mutant lamin A 
primarily targets human vascular cells as detected by an anti-Lamin A G608G 
antibody. Proc Natl Acad Sci U S A. Feb 14 2006;103(7):2154-2159. 
134. Morabito MA, Sheng M, Tsai LH. Cyclin-dependent kinase 5 phosphorylates the 
N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J 
Neurosci. Jan 28 2004;24(4):865-876. 
135. Bottos A, Rissone A, Bussolino F, Arese M. Neurexins and neuroligins: synapses 
look out of the nervous system. Cell Mol Life Sci. Aug 2011;68(16):2655-2666. 
136. Valiron O, Chevrier V, Usson Y, Breviario F, Job D, Dejana E. Desmoplakin 
expression and organization at human umbilical vein endothelial cell-to-cell 
junctions. J Cell Sci. Aug 1996;109 ( Pt 8):2141-2149. 
137. Zhou X, Stuart A, Dettin LE, Rodriguez G, Hoel B, Gallicano GI. Desmoplakin is 
required for microvascular tube formation in culture. J Cell Sci. Jul 1 2004;117(Pt 
15):3129-3140. 
138. Negash S, Wang HS, Gao C, Ledee D, Zelenka P. Cdk5 regulates cell-matrix 
and cell-cell adhesion in lens epithelial cells. J Cell Sci. May 15 2002;115(Pt 
10):2109-2117. 
139. Nakano N, Nakao A, Ishidoh K, et al. CDK5 regulates cell-cell and cell-matrix 
adhesion in human keratinocytes. Br J Dermatol. Jul 2005;153(1):37-45. 
140. Bera TK, Zimonjic DB, Popescu NC, et al. POTE, a highly homologous gene 
family located on numerous chromosomes and expressed in prostate, ovary, 
testis, placenta, and prostate cancer. Proc Natl Acad Sci U S A. Dec 24 
2002;99(26):16975-16980. 
141. Bera TK, Saint Fleur A, Lee Y, et al. POTE paralogs are induced and differentially 
expressed in many cancers. Cancer Res. Jan 1 2006;66(1):52-56. 
142. Das S, Ise T, Nagata S, Maeda H, Bera TK, Pastan I. Palmitoylation of POTE 
family proteins for plasma membrane targeting. Biochem Biophys Res Commun. 
Nov 23 2007;363(3):751-756. 
106  6  REFERENCES  
143. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of 
cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 
complexed with roscovitine. Eur J Biochem. Jan 15 1997;243(1-2):518-526. 
144. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of 
the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. Dec 
10 2002;102(5):463-468. 
 
7 APPENDIX 
  
108  7  APPENDIX  
7.1 Publications 
7.1.1 Original publications 
Weitensteiner SB, Liebl J, Krystof V, Günther, M, Pechan P, Strnad M, Fürst R, 
Vollmar AM, Zahler S  
Novel Cdk inhibitors as potent anti-angiogenic compounds in vitro and in vivo. 
in preparation 
 
Liebl J, Weitensteiner SB, Vereb G, Takács L, Fürst R, Vollmar AM, Zahler S 
Cyclin-dependent kinase 5 regulates endothelial cell migration and 
angiogenesis. 
J Biol Chem 2010 Nov 12;285(46):35932-43. Epub 2010 Sep 7. 
7.1.2 Poster presentations 
Weitensteiner SB, Liebl J, Krystof V, Günther, M, Pechan P, Strnad M, Fürst R, 
Vollmar AM, Zahler S  
Novel Cdk inhibitors as potent anti-angiogenic compounds. 
8th International Symposium on the Biology of Endothelial Cells (EC8),  
Zürich, June 15 - 18, 2011 
 
Weitensteiner SB, Liebl J, Krystof V, Günther, M, Pechan P, Strnad M, Fürst R, 
Vollmar AM, Zahler S 
Novel Cdk inhibitors as potent anti-angiogenic compounds.  
77. Jahrestagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie 
(DGPT) 
Frankfurt/Main, March 30 - April 01, 2010 
 
Weitensteiner SB, Heiskanen S, Liebl J, Vollmar AM, Zahler S 
Cyclin-dependent kinase 5 (Cdk5) upstream regulation in HUVECs.  
51. Jahrestagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie 
(DGPT) 
Mainz, March 23-25, 2009  
7  APPENDIX 109 
7.2 Curriculum Vitae 
 
Personal data  
Name Sabine Bianca Monika Weitensteiner 
Date of birth September 22, 1982 
Place of birth Tirschenreuth 
 
Education 
July 2008-October 2011 PhD thesis at the department of pharmacy, 
pharmaceutical biology, LMU Munich, Prof. Dr. S. 
Zahler, Prof. Dr. A.M. Vollmar 
July 2008 Licensure as a pharmacist (Approbation) 
Mai 2007-April 2008 Compulsory Internship (Pharmaziepraktikum) 
 Zweibrückenapotheke, München  
 (November 2007-April 2008) 
 HEXAL AG, Holzkirchen 
 (Mai 2007-October 2007) 
October 2002-April 2007 Study of Pharmacy, Universität Regensburg 
August 2005 Internship, University Hospital Pharmacy, 
Universidade de Coimbra, Portugal 
1993-2002 Stiftland-Gymnasium Tirschenreuth 
 
Working experience 
September 2008 – present  Pharmacist, Löwen-Apotheke, München 
  
110  7  APPENDIX  
7.3 Acknowledgements  
Diese Arbeit wurde im Department Pharmazie der LMU am Lehrstuhl für 
Pharmazeutische Biologie von Frau Professor Dr. Angelika M. Vollmar unter Betreuung 
von Herrn Professor Dr. Stefan Zahler angefertigt. Ihnen möchte ich an allererster 
Stelle danken für die Möglichkeit in Ihrer Arbeitsgruppe zu promovieren. Die 
hervorragende fachliche und persönliche Betreuung, viele anregende Diskussionen 
und die Bereitschaft, sich immer die Zeit für Ihre Mitarbeiter zu nehmen hat großen 
Anteil am Gelingen dieser Doktorarbeit – dafür ein großes Dankeschön. Vielen Dank 
an dieser Stelle auch Frau Dr. Johanna Liebl und Herrn PD Dr. Robert Fürst für 
wertvolle Hilfestellungen und viele fachliche Anregungen. 
Herzlicher Dank gilt auch allen weiteren Mitgliedern meines Prüfungskomitees für Ihre 
Zeit und Mühe: Prof. Dr. Christoph W. Turck, Prof. Dr. Franz Bracher, Prof. Dr. 
Christian Wahl‐Schott und Prof. Dr. Ernst Wagner.  
Besonderer Dank geht auch an die an dieser Arbeit beteiligten Kooperationspartner:  
Herrn Professor Dr. Turck und Frau Dr. Giuseppina Maccarrone vom Max-Planck-
Institut für Psychiatrie, München, für die Durchführung der LC-ESI-MS/MS-Analysen, 
Dr. Vladimir Krystof und Dr. Radek Jorda vom Laboratory of Growth Receptors, 
Institute of Experimental Botany, Palacky University, Olomouc, CZ, für die 
Bereitstellung der Cdk-Inhibitoren, und Dr. Michael Günther vom Lehrstuhl für 
Pharmazeutische Biologie und Biotechnologie, Department Pharmazie der LMU 
München, für die Durchführung der Tierversuche.  
Vielen Dank Bettina, Hanna und Elisabeth für das Korrekturlesen.  
Ein ganz besonders großes Dankeschön geht an alle ehemaligen und derzeitigen 
Mitglieder der Arbeitsgruppe: für die herzliche Aufnahme, die großartige 
Arbeitsatmosphäre für und die Tatsache, dass man hier jeden (fast) immer um Rat und 
Hilfe bitten kann – und natürlich auch für den Spaß in- und außerhalb des Labors. Im 
Besonderen: Meinem „Gegenüber-Boxenluder“ Elisabeth – Großes Danke für viel 
Spaß und konstanten moralischen Beistand in allen Lebenslagen. Meinem „Ex-
Boxenluder“ Bettina vielen Dank für die geduldige Beantwortung aller Fragen zu 
Westernblot, Word-Formatierung und weiterem. Jana, Bianca, Kerstin, Frau Schnegg 
und Rita: Danke für große Hilfe im Labor! Romina – Danke für die angenehme Zeit im 
D-Zimmer. Sebastian – Danke fürs Aufpassen! Allen früheren und jetzigen 
„Bewohnern“ im Endothel-Labor: Lena, Martin, Michi – Danke, hat Spaß gemacht! 
Suvi, Katharina und Tanja – Danke für fleißige Mitarbeit am Projekt! 
7  APPENDIX 111 
Zuletzt gibt es noch ein riesiges Dankeschön an meine Eltern und meine Schwester 
Julia. Danke für eure stetige und bedingungslose Unterstützung, ohne Euch wär ich 
nicht so weit gekommen.  
 
